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The action of thrombin is central to the processes of thrombosis and haemostasis.
Thrombin is generated following the activation of prothrombin by 'prothrombinase' (II-
ase), the phospholipid membrane-bound factor Xa (fXa)-factor Va (fVa) complex,
which in turn is dependent upon the generation of fXa by intrinsic 'tenase' (X-ase), the
phospholipid membrane-bound factor IXa (flXa)-factor Villa (fVIIIa) complex.
Thrombin not only converts fibrinogen to fibrin, but also amplifies its own formation
by activating the cofactors in II-ase and X-ase, factor V and factor VIII, respectively.
The critical role played by II-ase and X-ase towards thrombin generation makes these
membrane-bound enzyme complexes attractive targets for inhibition and offers an
effective approach to blocking coagulation. Heparin acts as an anticoagulant by
activating antithrombin (AT), which then inactivates thrombin, fXa and other
activated clotting factors. However, the heparin-AT complex has limited activity
against membrane-bound fIXa and fXa. Recently, in buffer systems, heparin has been
shown to have an AT-independent effect on coagulation by directly inhibiting X-ase,
an effect that is minimal in plasma where the AT-dependent effect predominates
(Barrow et al. 1994a). To capitalise on this AT-independent effect, heparin was
chemically modified by periodate oxidation and borohydrate reduction to lower its
affinity forAT (from Kd value of 25nM to 43pM); we used LMWH rather than heparin
to take advantage of the superior pharmacokinetic profile of LMWH. Using this low
affinity LMWH (LA-LMWH), N-desulphated LMWH was prepared using a solvolytic
desulphation method. Whereas LA-LMWH inhibited X-ase to a similar extent as
LMWH with high AT-affinity (IC50 of 16pg/ml and 13pg/ml respectively), N-
desulphated LMWH had minimal inhibitory activity (IC50 of 166pg/ml). These
findings indicate that the inhibition ofX-ase by LMWH is AT-independent but charge-
dependent. To test this concept, LA-LMWH was progressively hypersulphated using
sulphur trioxide as a donor. Maximally hypersulphated LMWH (sLMWH) was not only
a 32-fold more potent inhibitor of X-ase than LMWH (IC50 reduced from 16pg/ml to
0.5pg/ml), but also acquired Il-ase inhibitory activity, with an IC50 of 30pg/ml. In
plasma systems, sLMWH had similar AT-independent effects on X-ase and Il-ase.
Using the activated partial thromboplastin time to reflect the activity of X-ase and Il-
ase, and the fXa-clotting time to reflect the activity of Il-ase, sLMWH prolonged both
clotting times in AT-depleted and control plasma to the same extent. In contrast,
unfractionated heparin had no effect on either clotting test in AT-depleted plasma.
When the effect of sLMWH on various components of X-ase and Il-ase was examined,
the inhibitory effect was found to be cofactor-dependent (fVa/fVIIIa) and phospholipid-
independent. Although assembly and function of Il-ase and X-ase on synthetic
phospholipid vesicles differs from that on platelets, sLMWH directly inhibited both
enzyme complexes on the surface of isolated, washed human platelets. Determination
of turnover numbers of both enzyme complexes in the presence of increasing
concentrations of sLMWH indicates a differential inhibitory effect, with almost
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complete inhibition of fXa generation by X-ase. To further explore the mechanism of
inhibition, the Michaelis constant, Km, and kcal of the fXa/fVa complex for
prothrombin, and of the flXa/fVIIIa complex for fX were determined kinetically, in the
presence of a saturating concentration of phospholipid (24-50pM), and in the absence
or presence of sLMWH. In the presence of 500pg/ml sLMWH, the kcal was reduced 3-
fold for II-ase, whereas the Km was unchanged at 0.16pM, consistent with a non¬
competitive mechanism of inhibition. A similar pattern of inhibition was seen with X-
ase; in the presence of 0.5pg/ml sLMWH, kcat was reduced 4-fold, with minimal
changes in Km. By acting as a potent direct inhibitor of X-ase and II-ase, sLMWH acts
as an anticoagulant in a novel fashion.
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Arterial thrombosis is triggered by vascular injury. Spontaneous or traumatic
rupture of atherosclerotic plaque exposes tissue factor (TF) which complexes factor
VII/VIIa (fVII/VIIa) and triggers coagulation (Davie, 1995) by activating factor IX (flX)
and factorX (fX)(Broze, 1995a). Although dampened by tissue factor pathway inhibitor
(TFPI)(Broze, 1995b), sufficient factor Xa (fXa) is generated by TF/VIIa to form
thrombin by "prothrombinase", the phospholipid-membrane bound factor Va (fVa)-
factorXa (fXa) complex. In turn, the thrombin generated allows platelet aggregation and
activation of the cofactors, factor V (fV) and factor VIII (fVIII). Through the activation
of factor IX (flX), sufficient fXa is generated by "intrinsic tenase", the phospholipid-
membrane bound factor Villa (fVIIIa)-factor IXa (flXa) complex, to maintain
haemostasis (Broze, 1995a). The critical role of intrinsic tenase and prothrombinase in
the coagulation pathway makes these enzyme complexes attractive targets for inhibition,
and provides a highly effective approach to block coagulation.
Heparin is a widely used anticoagulant (Hirsh et ah, 1995), but has pharmacokinetic
and biophysical limitations (Hirsh, 1991)(Eisenberg et al., 1993)(Hogg and Jackson,
1985). The biophysical limitations reflect, in part, the inability of the heparin-
antithrombin complex to inactivate fXa bound to platelets within prothrombinase
(Marciniak, 1973)(Speijer et ah, 1995)(Teitel and Rosenberg, 1983), as well as flXa
within intrinsic tenase.
Heparin acts as an anticoagulant by activating antithrombin (AT), which inactivates
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fXa and thrombin (Rosenberg, R. D., 1987). Recently, in buffer systems, heparin and
low molecular weight heparin (LMWH) have been shown to have antithrombin-
independent effects on blood coagulation by the direct inhibition of intrinsic tenase, but
have no inhibitory effect on the function of prothrombinase (Barrow et al., 1994a). In
plasma systems, the antithrombin-dependent anticoagulant effect predominates. To
capitalise on the antithrombin-independent effect, heparin was chemically modified to
reduce its affinity for antithrombin from a Kd value of 25nM to 43pM (unpublished
results) using a technique of periodate oxidation followed by borohydride reduction
(Young and Hirsh, 1990). We used LMWH rather than unfractionated heparin to take
advantage of the superior pharmacokinetic profile of LMWH (Hirsh and Levine, 1992;
Weitz, 1997).
The aim of this study was to explore methods of increasing the potency of LMWH.
For this purpose, the low affinity LMWH (LA-LMWH) was N-desulphated by a
desulphation solvolytic technique (Inoue and Nagasawa, 1976). Preliminary results
indicated that N-desulphated LMWH had minimal inhibitory activity compared to LA-
LMWH, suggesting that the inhibition of intrinsic tenase by LMWH was charge-
dependent. To test this hypothesis, LA-LMWHwas progressively hypersulphated using
sulphur trioxide as a sulphate donor and the effect of these hypersulphated LA-LMWH
(sLMWH) fractions on intrinsic tenase and prothrombinase was examined.
1.1 The Importance of Intrinsic Tenase and Prothronibinase in Thrombin
Generation :
The function of the haemostatic mechanism is to maintain blood in its fluid state
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and to stop catastrophic blood loss from severed vessels. Maintenance of haemostasis
includes interactions between endothelium, platelets and coagulation factors (Nesheim,
1984; Furie and Furie, 1988).
It is currently believed that the haemostatic process does not end with the
generation of fXa and thrombin. Instead, the initial haemostatic response must be
"consolidated" by the progressive local generation of fXa and thrombin, reflecting the
continuous removal of activated cofactors by blood flow, inactivation by protease
inhibitors and the competing process of fibrinolysis (Broze, 1995a). In normal
haemostasis, the activated fVII/fVIIa-TF complex (extrinsic 'tenase') is responsible for
initial fXa generation, and subsequently provides sufficient thrombin by
"prothrombinase", the phospholipid membrane bound fXa-fVa complex, to induce local
aggregation of platelets and activation of fV and fVIII (Rapaport and Rao, 1995).
However, fXa produced by fVIIa/TF is dampened by tissue factor pathway inhibitor
(TFPI) (Schneider, 1947; Thomas, 1947; Broze and Miletich, 1987; Broze, 1995a) and
is insufficient to sustain haemostasis. TFPI, amultivalent Kunitz-type inhibitor oftissue
factor-induced coagulation which directly binds and inhibits fXa, produces feedback
inhibition of the fVIIa-TF catalytic complex in a fXa-dependent manner (Broze et al.,
1988; Girard et al., 1989; Girard and Broze, 1993). Factor Xa produced by fVIIa/TF
must be amplified through the actions of flXa and fVIIIa within the "intrinsic tenase"
complex, the phospholipid membrane bound flXa-fVIIIa complex, to maintain
haemostasis (Broze, 1995a) (see figure 1). As a result of the central roles of intrinsic

















Figure 1 : Schematic representation of the coagulation cascade, revised in 1995.
(Adapted from Broze. G.J., 1995.) Coagulation is initiated at a site of vessel damage
following the exposure of fVIIa to tissue factor. As a result of the feedback inhibition
of the fVIIa/TF complex by TFPI, factors VIII, IX and XI are required for the
production of additional fXa.
directly inhibit the activity of these complexes.
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1.2. The Surface Membrane Enzyme Complexes, Prothrombinase and Intrinsic
Tenase :
The three prominent enzyme systems that exist within the coagulation pathway are:
extrinsic tenase, intrinsic tenase and prothrombinase (see figure 2). Although the
extrinsic pathway is responsible for initiation of coagulation, it has a limited role in its
propagation. In addition, this system is dependent on components not constitutively
present in blood. For these reasons, the extrinsic tenase complex will not be considered
further.
Prothrombinase and intrinsic tenase share similar properties. Each complex
consists ofa vitamin K- dependent serine protease and a non-proteolytic cofactor protein
(see figure 3). The reactions are Ca2+ dependent and require a negatively charged
phospholipid surface for the optimal expression of activity within a physiological time
scale (Nesheim, 1984)(Mann, 1987)(Mannet ah, 1988)(Mannet ah, 1990).
1.2.1. The Prothrombinase Complex
The prothrombinase complex is the terminal complex of the blood coagulation
cascade and is composed ofthe serine protease, fXa, associated with the protein cofactor
fVa, assembled on a cellular membrane (Krishnaswamy et ah, 1987) (Miletich et ah,
1978)(Miletich et ah, 1978)(Kane et ah, 1980)(Tracy et ah, 1983) in the presence of
calcium ions (Jenny and Mann, 1989)(Mann et ah, 1988)(Mann, 1987). The complex
can also be assembled in vitro using synthetic phospholipid vesicles (Nesheim et ah,
T







Schematic diagram showing the Enzyme Complexes of the Coagulation Cascade.
The prothrombinase and intrinsic tenase complexes share structural and functional
similarities; each complex consists of a vitamin K-dependent serine protease and a
non-proteolytic cofactor protein. Reactions are calcium-dependent, and also require
a negatively charged phospholipid surface.
(Adapted from Mann. 1988)
Figure 3 : Diagrammatic representation of the prothrombinase & intrinsic
tenase complexes. Structural and functional similarities between the
constituents of both complexes suggest that they assemble in a similar
manner on a membrane lipid bilayer. (Adapted from Nesheim. 1984).
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1979). The complex catalyses the proteolytic activation ofprothrombin to thrombin via
the proteolysis of two peptide bonds. (Krishnaswamy, 1990)(Krishnaswamy et al.,
1993).
Equilibrium binding studies indicate that the prothrombinase complex consists
of a phospholipid-bound 1:1 complex of fVa and fXa (Krishnaswamy, 1990) such that
fVa constitutes a "receptor" for fXa (Nesheim, 1984)(Tracy and Mann, 1983). Factor
Va interacts with the phospholipid membrane via its light chain; fXa , which also
interacts with the phospholipid membrane, interacts with the light chain of fVa, and
prothrombin interacts with the heavy chain of fVa. The membrane bound complex
allows for localisation, amplification and modulation of the reaction (Nesheim,
1984.,Tracy and Mann, 1983).
Stopped-flow kinetic studies of prothrombinase assembly have led to the
formulation of a model for assembly of the complex (Krishnaswamy et al., 1988)(Mann
et al., 1990). The rate-limiting combination of fVa and fXa, each with separate
combining sites on the vesicle surface, are the initial steps required for the formation of
the prothrombinase complex (Krishnaswamy, 1990) (see figure 4). The formation of the
protein-phospholipid binary complexes are mutually exclusive, indicating that fXa and
fVa bind to identical or overlapping sites on the membrane surface (Krishnaswamy,
1990).
Subsequent reaction(s) between membrane-bound proteins are thought to represent
rapid reaction steps involving "translational" or "rotational diffusion" of the protein-
phospholipid binary complexes on the vesicle surface to form prothrombinase.




Catalytic Advantage of Prothrombinase Complex Formation
The catalytic advantage associated with formation ofprothrombinase is shown by
the data in Table I, which compare relative rates of prothrombinase activity catalysed
by different combinations of components of the enzyme complex at physiological
concentrations (Mann et al., 1988)(Nesheim, 1984)(Mann, 1987). The relative rate
increases 300,000-fold when the complete complex is assembled (Nesheim et al.,
1979)(Mann, 1987).
Kinetic studies show that the phospholipid component contributes to a reduction
in Km (the Michaelis constant, the substrate concentration at which the reaction rate is
halfmaximal, and a measure of the affinity of the enzyme for the substrate) while fVa
contributes to a rise in kcat (a rate constant for the activation of the substrate at saturating
concentration) (Mann, 1987)(Nesheim, 1984)(Rosingetal., 1980)(Nesheim, 1979). The
mechanism responsible for each of these effects will be discussed in turn.
The Contribution of the Membrane Surface to the Enhanced Catalytic Rate of
Prothrombinase :
The plasma membrane consists of a complex array of lipids and protein in the form
of a lipid bilayer interspersed with penetrating or attached proteins (Morrow et al.,
1994). The distribution of lipids has been established experimentally by the use of
phospholipases and chemical labels (Schick et al., 1976)(Bevers et al., 1982a). In both
erythrocyte and platelet plasma membranes, the negatively charged phospholipids,
phosphatidyl serine and phosphatidylinositol, which possess potent procoagulant activity
12
TABLE I
Relative Rates of Prothrombin Activation in the Presence of Various
Combinations of the Components of the Prothrombinase Complex
Components present Relative Rate (%)*
Xa, Ca2+, phospholipid, Va 100
Xa, Ca2+, Va 0.13
Xa, Ca2+, phospholipid 0.008
Xa, Ca2+ 0.0007
Xa 0.0003
Proteins are present at physiological concentration:
Prothrombin : 10"6 M
fVa: 10"8M
fXa : 10'9M
Phospholipid is present at a concentration adequate to saturate the reaction
* Relative rates are expressed in comparison to prothrombinase.
(Adapted from Mann. 19871
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(Zwaal et al., 1977) are almost exclusively located in the inner leaflet (Bevers et al.,
1982b).
Platelet activation by collagen or thrombin, or by calcium ionophore, causes
transbilayer movement of phospholipids resulting in increased exposure of
phosphatidylserine in the outer leaflet of the membrane bilayer (Bevers et al, 1982a)
(Comfurius, 1996). Although transverse diffusion ofphospholipids ("flip-flop")(Bevers
et al., 1983) is an extremely slow process in vesicles of pure phosphatidylcholine, as the
polar head group of this molecule limits its passage through the hydrophobic lipid
bilayer (Higgins, 1994), rapid "flip-flop" in artificial and natural membranes has been
reported (Op Den Kamp, 1979) and is an active process requiring ATP (Devaux et al.,
1991). Membrane proteins ("flippases") have recently been identified and cloned (Zhou,
1997) which catalyse rapid calcium-dependent (Zhou et al., 1998) (Ruetz and Gros,
1994) transbilayermovement ofphospholipids (Hensleit et al., 1990); this "phospholipid
scramblase" activity may be involved in the loss of lipid asymmetry that occurs during
cellular activation, injury or apoptosis (Comfurius et al., 1996).
The mechanism by which phosphatidylserine-containing membranes enhance
activity of the fIXa-Villa complex and fXa-fVa complex has been an area of
considerable interest in the current literature (Mann et al., 1990). Originally, the
membrane was believed to enhance the assembly of enzyme, cofactor and substrate
(Nesheim, 1984a)(Nesheim et al., 1984b) (see appendix (i)). There is now evidence that
individual phospholipid molecules alter the catalytic process for the cofactor-enzyme
complex, in addition to enhancing enzyme-substrate binding (Gilbert and Arena,
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1996)(Gilbert and Arena, 1997). In support of this concept, Kung and colleagues
reported that membranes composed entirely of saturated phospholipids allow normal
assembly of fXa and fVa to take place (Kung et ah, 1994), with a normal Michaelis
constant for prothrombin, but the catalytic step is greatly slowed. Additionally, Koppaka
and coworkers demonstrated that soluble phosphatidylserine binds fXa and alters its
catalytic activity (Koppaka et ah, 1996).
The Contribution of Activated Cofactor to the Enhanced Catalytic Rate of
Prothrombinase :
Factor Va accelerates the catalytic rate of prothrombinase by increasing the kcat
for product formation. Historically, this has been attributed to an increase in the binding
of the enzyme to the phospholipid surface and to alterations in the reaction pathway that
occur in the presence of fVa. In the presence of fVa, the initial cleavage of (bovine)
prothrombin occurs at the Arg323-Ile324 bond generating meizothrombin as the principal
intermediate (Rosing and Tans, 1988)(Krishnaswamy et ah, 1986); in contrast, without
fVa, the initial cleavage of (bovine) prothrombin occurs at Arg274-Thr275, generating
prethrombin-2, and subsequently thrombin, at a much slower rate.
In addition to the above mechanisms, the accelerating effects of fVa appear
related to the macromolecular substrate specificity of fXa (Krishnaswamy and Betz,
1997)(Betz and Krishnaswamy, 1998). Studies with tick anticoagulant peptide (TAP),
a potent and highly selective fXa inhibitor obtained from the soft tick, Ornithodoros
moubata (Waxman et al., 1990), and mutant TAP derivatives, have provided evidence
for fVa-induced changes at extended macromolecular recognition sites (or "exosites")
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in fXa upon its incorporation into prothrombinase (Betz et al., 1997). It is possible that
the function of fVa is to enhance a number of substrate binding steps in a multistep
pathway that governs the overall catalytic activity of the enzyme complex
(Krishnaswamy and Betz, 1997)(Betz and Krishnaswamy, 1998).
A model has recently been proposed by Krishnaswamy and colleagues which links
the ability of fVa to enhance the catalytic efficiency of fXa within prothrombinase, with
the narrowmacromolecular substrate specificity of fXa (Betz and Krishnaswamy, 1998).
Kinetic studies of prethrombin-2 cleavage by prothrombinase have been performed in
the presence or absence ofprothrombin fragments 1 and 2. Prethrombin-2. fragment 1.2
is an activation intermediate formed by cleavage of prothrombin at Arg274-Thr275.
Fragment 1, which contains the Gla-domain, mediates the high affinity interaction of
prothrombin with the phospholipid membrane and fragment 2 is responsible for binding
to fVa. Prethrombin-2 is unable to interact with either the surface membrane or fVa by
itself (Suttie et ah, 1977)(see figure 5). Studies have shown that occupation of the active
site of the enzyme, fXa, by inhibitors or peptidyl substrates, does not alter the affinity
of fXa for prethrombin-2 (Krishnaswamy and Betz, 1997). From these observations, a
scheme has been proposed involving an ordered two-step binding process. The first step
involves binding ofsubstrate via its exosite, whereas the second step involves interaction
at the active site prior to bond cleavage and product release (Betz and Krishnaswamy,
1998). This kinetic scheme is represented in figure 6.
1.2.2. The Intrinsic Tenase Complex
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Figure 5 : Schematic diagram of cleavage sites in prothrombin and derivatives of prethrombin-2.
(Adapted from Krishnaswamv and Walker.lQg?).
Thrombin formation requires cleavage of prothrombin at Arg323-Iie324 (R323) forming meizothrombin,
followed by Arg274-Thr275 (R274) by prothrombinase. In the absence of factor Va, cleavage at R274 forms
prethrombin 2 plus fragment 1.2. The fragment 1 domain mediates the high affinity interaction of
prothrombin with membranes; fragment 2 is responsible for binding factor Va. The site denoted by R15S
is subject to cleavage by thrombin which releases fragment 1 from either prothrombin or fragment 1.2.
The shaded area represents the ability of prethrombin-2 to interact tightly with the fragment 2 domain.
Prethrombin-2 requires further cleavage at R323 to form thrombin; prethrombin-2 cannot interact with
membranes or factor Va.
Prethrombin-2. Fragment 2 can bind factor Va.
Prethrombin 2. Fragment 1.2 can bind both factor Va and membranes.
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FIGURE 6 : Schematic diagram outlining the proposed kinetic scheme for the cleavage
of substrate (prethrombin-2, S) to product (thrombin, P) by the prothrombinase enzyme
complex (E) in the presence of active-site directed reversible inhibitor.
(Adapted from Krishnaswamv and Betz. 1997)
association with fVIIIa on a negatively charged membrane surface, in the presence of
calcium ions (Mann et al., 1988). The enzyme complex catalyses the activation of fX to
fXa by means ofhydrolysis of a single peptide bond at Arg,94-Ile195 (Lollar et al., 1993).
In the presence ofVilla, acidic phospholipid and calcium ions, the catalytic efficiency
of flXa towards fX is increased by several orders ofmagnitude, due to a decrease in Km
and an increase in k^, for the reaction. The decrease in Km can be accounted for by the
effect ofacidic phospholipids, whereas the increase in kcat can be ascribed to fVIIIa (van
Dieijen et al., 1981). Similar to the kcat effect already described in the homologous
prothrombinase complex (Rosing et al., 1980), the catalytic advantage conferred by the
binding of factors Villa, IXa and X to the phospholipid membrane is partly attributable
to the alteration of the active site structure of flXa that occurs when it binds to fVIIIa
(Mutucumarana et al., 1992).
Model of Intrinsic Tenase :
The X-ray crystal structure ofporcine flXa was reported in 1995 by Brandstetter
and colleagues (Brandstetter et al., 1995); flXa resembles a "tulip" with the catalytic
module representing the "flower", two interlaced EGF domains representing the "bent
stalk" and the N-terminal Gla-domain representing the "bulb" (see figure 7). According
to Brandstetter, the high affinity of flXa for fVIIIa implies an extended interaction
surface between the two factors, and binding sites of fVIIIa extend along the entire
concave surface of the flXa molecule (Brandstetter et al., 1995). It is proposed that the
arched flXa lies across fVIIIa, with the flXa surface providing most of the contacts. The
binding of fX to the opposite side of fVIIIa may force fXa cleavage sites close to the




FIGURE 7 : MODEL of INTRINSIC TENASE
Schematic diagram of a model of the intrinsic tenase complex (Brandstetter et al.. 1995).
The binding of fX to the opposite side of fVIIIa forces fXa cleavage sites close to the
substrate binding site of fIXa and provides the energy for "active site rigidification".
(Adapted from Brandstetter et al.. 19951
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substrate binding site of flXa and provides the energy for "active site rigidification".
Factor VIII binding sites for flXa have been localised to amino acid residues Ser558-
Gln565 and Arg698-Ser710 of the A2 domain (Fay et ah, 1994) and residues 1811-1818 of
the A3 domain (Lenting et ah, 1996).
Model for the Instability of the Intrinsic Tenase Complex :
The activity of intrinsic tenase decays with time, and reflects the lability of fVIIIa
(Fay et ah, 1996). This was originally observed and referred to as a "self-damping" by
Jesty, who observed that the rate and yield of fXa formed by intrinsic tenase decreased
with increasing flXa concentration and a constant level of fVIIIa (Jesty, 1990).
Two mechanisms potentially contribute to this decay :
(1) the inter-factor Villa subunit affinity between the A2 subunit and A1/A3-C1-C2
dimer (Lamphear and Fay, 1992) and,
(2) the inactivation of fVIIIa resulting from flXa-mediated proteolysis of the A1
subunit (O'Brien et al., 1992).
Factor Villa is a labile heterotrimer composed of the A,, A2 and A3-CrC2
subunits. The A, and A3-C,-C2 subunits are linked by metal ion bridge(s) forming a
structurally stable yet inactive dimer (Fay et ah, 1991b). The A2 subunit is weakly
associated with the dimer (Kd=260nM)(Lollar et ah, 1992) by electrostatic interactions
(Fay et ah, 1991a), and dissociates at physiological pH, resulting in loss of fVIIIa
activity (Fay et ah, 1996). Heterotrimeric human fVIIIa activity can be efficiently
reconstituted from the isolated A2 subunit and A,/A3-C,-C2 dimer at slightly acidic pFI
(Fay et ah, 1991 a). It has been shown that porcine fVIIIa can be stabilised by flXa in the
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presence of phospholipid and calcium; the active site of flXa is not necessary for this
effect since flXa modified with dansyl-Glu-Gly-Arg-CH2Cl (DEGR-CK), an active site
inhibitor, yields results similar to wild-type flXa (Lollar et ah, 1984). Prolonged
interaction of fVIIIa with flXa results in loss of fVIIIa activity due to proteolytic
cleavage within the A, subunit and is a concentration dependent effect (Lamphear and
Fay, 1992).
The relative importance of each mechanism towards the overall instability of
intrinsic tenase is dependent upon underlying reactant concentrations (Fay et ah, 1996).
At low reactant concentrations, (for example, 0.5nM fVIIIa and 5nM flXa), intrinsic
tenase decay is determined by a weak affinity interaction between the fVIIIa A2 subunit
and A,/A3-Ci-C2 dimer, and the residual activity of the enzyme complex reaches an
equilibrium. Fay and colleagues carried out an analysis using a mutant form of fVIII
(fVIIIR336I), which possesses an altered flXa cleavage site. Similar rates of intrinsic
tenase decay (0.12 min"1) were shown confirming the lack of contribution ofproteolysis
under these conditions (Fay et ah, 1996). When the concentration of flXa was increased
ten-fold, the initial rate of decay of intrinsic tenase containing native fVIIIa increased
(0.12 to 0.82 min"1) and paralleled the rate of proteolysis of the A, subunit (Fay et ah,
1996). These, and other results, suggest a model in which decay of intrinsic tenase
results from both fVIIIa subunit dissociation and flXa-mediated cleavage, depending
upon the relative concentration of reactants (Fay et ah, 1996).
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1.3. Heparin and Low Molecular Weight Heparin
1.3.1. Structure of Heparin
Heparin is a sulphated glycosaminoglycan composed of alternating residues of an
uronic acid and D-glucosamine (Bjork and Lindhal, 1982)(Rosenberg and Bauer,
1994)(Hirsh et al., 1995). Uronic acid residues are either L-iduronic acid (IdUA) or D-
glucuronic acid (GlcUA)(see panel 'A', figure 8), and D-glucosamine residues are either
N-sulphated (GlcNS03) or N-acetylated (GlcNAc)(panel 'B', figure 8).
Commercial preparations are usually isolated from porcine intestinal mucosa or
bovine lung, and are heterogeneous mixtures of polysaccharide chains ranging in
molecular weight from 3000 to 30,000, with a mean molecular weight of 15,000 (Hirsh
1991).
The amino sugar components may possess different degrees of sulphation; a
small proportion ofresidues are 3-0-sulphated, and the 3-0-sulphated GlcNS03 residues
can be either trisulphated or disulphated (Lindahl et al., 1980).
An unique combination of disaccharide units makes up the pentasaccharide
sequence (panel D, figure 8), that contains the high affinity binding site for antithrombin
(Lindahl et al., 1980)(Casu et al., 1981). This sequence occurs in only about one-third
of heparin chains and is randomly distributed (Andersson et al., 1976)(Hirsh, 1995).
Sulphate groups essential for high-affinity binding to antithrombin are shown by an
asterisk in panel D, figure 8 (Thunberg et al., 1982)(Andersson et al., 1976) (Casu,
1989).
IdUA IdUA GlcUA GlcUA
F ig u re 8 :
Schematic diagram showing the monosaccharide units identified in heparins
and typical heparin sequences, (adapted from D A I .an e. TI 1. in rl h a I 19 89)
Panel A : Uronic acid residues, either L-iduronic acid, or D-glucuronic acid, which
may be variably sulphated at carbon position 2.
Panel B : D-glucosamine residues, which may be either N-sulphated or N-acetylated.
Panel C : represents a typical heparin sequence; the amino sugar components may possess
different degrees of sulphation, and a small proportion of N-sulpho-a-D-glucosamine
residues may be 3-O-sulphated; only approximately 10-20% are glucuronic acid residues.
Panel D : represents the unique combination of disaccharide units that makes up the
pentasaccharide sequence" which contains the high affinity binding site forantithrombin.
Sulphate groups essential for high-affinity binding to antithrombin are shown by an asterisk.
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1.3.2. Anticoagulant Effects of Heparin :
Heparin acts as an anticoagulant by activating antithrombin; the heparin-
antithrombin complex then inactivates thrombin, fXa and other activated clotting factors
(Bjork and Lindhal)(Hirsh, 1991). Recently, studies in buffer systems have shown that
heparin also exerts an antithrombin-independent anticoagulant effect by blocking the
activity of intrinsic tenase (Barrow et ah, 1994a). In plasma systems, however, the
antithrombin-dependent effect of heparin predominates.
Antithrombin-dependent Anticoagulant Effect:
Antithrombin (previously known as "antithrombin III" and "heparin
cofactor")(Perry, 1994) has a molecular weight of 58,200 (Olson and Bjork, 1994) and
a prolate ellipsoid shape. The complete primary structure was reported by Petersen and
colleagues in 1979 (Petersen, 1979).
Antithrombin is a single chain glycoprotein with 432 amino acid residues
(Rosenberg, 1987). The mature protein has 3 disulphide bridges formed by cysteine
residues Cys8-Cys128, Cys21-Cys95 and Cys247 -Cys430 (Olson and Bjork, 1994)(Chandra
et ah, 1983)(Rosenberg, 1987), and four potential glycosylation sites at Asn96, Asn135,
Asn155 and Asn'92 (Perry, 1994)(01son and Bjork, 1994). A minor pool of normal
antithrombin (10% of the total plasma concentration) known as "ATp" lacks the
carbohydrate side-chain on Asn135 and is not glycosylated, resulting in a slightly higher
heparin affinity compared with the predominant form, "ATa" (Perry, 1994)(Lane et ah,
1996).
The location of "critical sites" within antithrombin, the reactive site, the potential
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heparin binding sites, the conformation-sensitive tryptophan, and the disulphide
crosslinks is shown in figure 9 (Rosenberg and Bauer, 1994)(Colman et ah, 1994).
In 1973, Rosenberg and Damus demonstrated that antithrombin neutralises the
activity of thrombin by forming a 1:1 stoichiometric complex between the reactive site
(Arg393)(also known as PI residue), of antithrombin, and the active centre (Ser394) of
thrombin (Rosenberg, 1975)(Rosenberg and Damus, 1973). Rapid kinetic studies have
demonstrated that the inactivation of thrombin by antithrombin is a two step process.
Initially the two reactants form a weak encounter complex, with a dissociation constant
of approximately 1.4x10"3 M, which is converted to a stable complex at a rate constant
ofapproximately 10s"1 (Olson and Shore, 1982). In the absence ofheparin, the apparent
second order rate constant for the inactivation of thrombin is 0.7 to 1.4 x 104Msat
25 to 37°C, and is increased to 1.5 to 4 x 10 7 M s in the presence of optimal
concentrations of heparin, increasing the reaction rate by 2000-fold (Olson and Bjork,
1994).
Heparin preparations are characterised by a subpopulation ofmolecules with high
affinity for antithrombin (Hook et ah, 1976). The high-affinity fraction, which
constitutes about one third of unfractionated heparin, and contains a unique
pentasaccharide unit, has high anticoagulant activity and accounts for about 90% of the
activity of commercial heparin (Choay et ah, 1983)(01son and Bjork, 1994). The
remaining low-affinity heparin has low specific activity (<10% of the high affinity
fraction). Most high affinity chains contain only one pentasaccharide sequence,
randomly distributed along the chains, although some longer chains may contain two
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Figure 9 : "Critical sites" within antithrombin : Arg-393-Ser-394 is the reactive
of antithrombin. Trp-49 is the conformation-sensitive aromatic residue. The various
lysine and arginine residues are potential sites for the binding of the different domains
ofheparin to the protease inhibitor.
(Adapted from Colman. Hirsh, Marder. Salzman. 1994)
KEY
• carbohydrate attachment sites
O exposed loop on protein surface
disulphide bridge important for heparin binding conformation
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pentasaccharide units (Olson and Bjork, 1994).
Four negatively charged sulphate groups in the pentasaccharide sequence bind
to a single positively charged site on antithrombin (Kd = 1 -2 x 10 "8M, at pH 7.4, ionic
strength 0.15) (Olson and Bjork, 1994)(Kridel and Knauer, 1997) located on and
adjacent to the D-helix (see figure 9). Studies using stopped flow fluorimetry have
highlighted the kinetics ofhigh affinity heparin binding to human antithrombin. Binding
to the pentasaccharide units results in a conformational change which is thought to take
place at the reactive site loop of antithrombin, converting it into a very rapid inhibitor
(Olson and Bjork, 1994)(Huntington, J. A. et al., 1996).
Heparin binds to "anion-binding exosite II" on thrombin (Stubbs and Bode,
1993), an electropositive patch located on the surface of thrombin, remote from the
catalytic site. The interaction of heparin with thrombin is pentasaccharide-independent
and involves any number of non-specific sites on the heparin molecule. Subsequent
diffusion along the surface of the polysaccharide allows thrombin to interact with
antithrombin. Thus, heparin promotes a thrombin-antithrombin interaction through a
"surface approximation" or "bridging"of the two proteins on the heparin surface (Olson
et al., 1993). Heparin molecules require at least 13 saccharide units in addition to the
pentasaccharide unit for bridging of thrombin to occur (Olson et al., 1993). Virtually all
unfractionated heparin molecules that possess the pentasaccharide sequence contain at
least 18 saccharide units (5400Da). In contrast, only 25-50% of low molecular weight
heparin chains are of sufficient length to bind both thrombin and antithrombin. Heparin
molecules that contain fewer than 18 saccharides are too short to bind both thrombin and
28
antithrombin simultaneously, and are unable to fully accelerate the inactivation of
thrombin by antithrombin, but retain the ability to catalyse the inhibition of factor Xa
by antithrombin (Olson etal., 1993)(Weitz,1997). Consequently, unfractionated heparin
has equivalent activity against fXa and thrombin, and has an anti-fXa to anti-IIa ratio of
1:1, whilst low molecular weight heparins (LMWHs) (mean MW 4000-6500) have
greater activity against fXa, and have anti-fXa to anti-IIa ratios of between 4:1 and
2:l(Weitz, 1997)(Hirsh and Levine, 1992).
Antithrombin-Independent Mechanisms of Inhibition :
In a discontinuous plasma-free assay of fX activation by intrinsic tenase, using
purified human and porcine coagulation factors, Barrow and colleagues demonstrated
that both unfractionated heparin and LMWH directly inhibit the activation of fX, with
IC50 values of lpg/ml, and 6pg/ml respectively (Barrow et ah, 1994a). In contrast, they
have no effect on prothrombinase activity at concentrations up to lOpg/ml. Heparin
produced a small increase in extrinsic tenase activity, consistent with other data in the
literature (Broze, Jr. et al., 1993).
The kinetics of fX activation in the presence ofheparin were further analysed to
establish the mechanism by which heparin inhibits intrinsic tenase. At fixed
concentrations of fIXa, fVIIIa and phospholipid, the dependence of the initial velocity
of fX activation on substrate (fX) concentration follows Michaelis-Menten kinetics, and
heparin caused a non-competitive pattern of inhibition (Barrow et al., 1994a).
Heparin also directly inhibits the activation of the fVIII-vWf complex by
thrombin (Barrow et al., 1994b), by inhibiting heavy chain cleavages of fVIII at Arg372
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and Arg740 , and light chain cleavage at Arg1689. This suggests that the recognition of
fVIII by thrombin involves "exosite 2". Further studies using a recombinant exosite 2
defective mutant, "thrombin RA", and hirugen, (a synthetic N-acetylated
dodecapeptide), which competitively inhibits binding of macromolecules to exosite 1,
were used by Esmon and Lollar to investigate the role of anion binding exosites 1 and
2 in the activation of factors V and VIII. ("Exosite 1" is a surface patch of highly
positive charge density, distinct from the active site of thrombin, which binds
fibrinogen, 5th and 6th EGF-like domains of thrombomodulin and the COOH-terminal
domain of hirudin) (Stubbs and Bode, 1993). It was found that hirugen inhibits fV and
fVIII activation by thrombin. In addition, the catalytic efficiency of the activation of
thrombin, or of the first step of fV activation by thrombin RA was only 10% that of
wild-type thrombin, although the overall rate of conversion to fVa was not influenced
by thismutation. These results indicate that both exosites are involved in the recognition
of fV and fVIII by thrombin, although there are significant differences in the nature of
thrombin's interaction with these two substrates (Esmon and Lollar, 1996).
1.4. Objectives
In plasma systems, the antithrombin-dependent effect of heparin predominates.
To capitalise on the antithrombin-independent effect described in recent studies in buffer
systems (Barrow et al, 1994a), LMWH was chemically modified by periodate oxidation
followed by borohydride reduction (Young and Hirsh, 1990), a technique that
selectively cleaves bonds ofnon-sulphated uronic acid residues. This reduces the affinity
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LMWH for antithrombin by 1500-fold (from a Kd value of 25nM to 43pM). After
demonstrating that this chemicallymodified LMWH derivative inhibited intrinsic tenase
to the same extent as the starting material, we then explored methods of increasing the
potency of LMWH. As a first step, N-desulphated LMWH was prepared using a
solvolytic desulphation technique (Inoue and Nagasawa, 1976). In contrast to the
startingmaterial, N-desulphated LMWH had minimal inhibitory activity. These findings
indicated that the inhibition of intrinsic tenase was antithrombin-independent, but
charge-dependent. To capitalise on the charge-dependent effect, LMWH with low
affinity for antithrombin was sulphated using sulphur trioxide as a sulphate donor,
providing a series of increasingly hypersulphated, low affinity, low molecular weight
heparins.
The first objective was to investigate the inhibitory effect of this series of
LMWHs on intrinsic tenase and prothrombinase activity in buffer systems. Using kinetic
studies, I explored the possibility that an increase in the extent ofsulphation ofLMWH,
and thereby an increase in the overall negative charge of the compound, might lead to
an increase in inhibitory potency.
The second objective was to determine the mechanism of inhibition by
examining the influence ofa hypersulphated LMWH on partially reconstituted activation
complexes to demonstrate the component(s) responsible for glycosaminoglycan
sensitivity.
The third objective of this study was to establish the type of inhibition by
investigation of kinetic parameters, namely, the turnover number, kca„ an estimation of
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the catalytic rate of the enzyme complex, the Michaelis constant, Km, a measure of the
affinity of the enzyme towards the substrate, and the apparent dissociation constant,
Kdapp, a measure of the affinity of the enzyme, or the cofactor, towards the rest of the
assembled complex. These measurements were derived from calculations based on
classical Michaelis Menten kinetics.
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Human factors V, Ya and IXa were obtained from Haematologic Technologies
Inc. (Essex Junction, VT), and factors Xa, prothrombin, factor X and a-thrombin were
obtained from Enzyme Research Laboratories (South Bend, IN). Monoclonal-purified
human fVIII (Hemofil) was obtained from Baxter, and recombinant fVIII (Kogenate)
from Bayer Inc., Etobicoke, Ontario. Albumin-free fVIII was a gift from Dr E. Saenko,
Holland Laboratory, American Red Cross, Rockville, Maryland. The purity of factors
V and VIII were assessed by SDS-PAGE (Laemmli, 1970), and to exclude the
possibility that flXa was contaminated with either fXa or thrombin, or fXa was
contaminated with thrombin, chromogenic assays with N-methoxycarbonyl-D-
norleucyl-L-arginine-4-nitranilide-acetate(Chromozym.X) and Tosyl-glycyl-prolyl-
arginine-4-nitranilide-acetate (tGPR-pNA), fXa and thrombin-directed substrates,
respectively, were performed.
L-a-phosphatidylchoIine (Type III-E from egg yolk), L-a-phosphatidyl-L-serine
(from bovine brain) and tGPR-pNA were obtained from Sigma Chemical Co., St Louis,
MO. Chromozym.tPA(N-methylsulfonyl-D-phenyl-Ala-Gly-Arg-4-nitranilide-acetate),
and Chromozym.X were obtained from Boehringer Mannheim, West Germany. S2444
(L-Pyroglutamyl-glycyl-L-arginine-p-nitroaniline-hydrochloride) and S2222 (N-
Benzoyl-L-isoleucyl-L-glutamyl-glycyl-L-arginine-p-nitroanilinehydrochloride) were
obtained from Chromogenix, Sweden. Pefachrom-IXa (Pefa 3107) was obtained from
Pentapharm.Ltd, Basel, Switzerland. Polybrene (Hexadimethrine bromide) was
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purchased from Aldrich Chemical Co., Oakville, Ontario. Prostaglandin El was
purchased from Sigma, and A23187 from Molecular Probes, Eugene, Oregon.
Unfractionated Grade 1 sodium heparin (184USP units/mg) from porcine
intestinal mucosa and dextran sulphate, MW 5000, were purchased from Sigma. V20-
AMS was obtained from Scientific Protein Labs, Milwaukee, WI; Supersulphated low
molecular weight heparin (SS-LMWH) was obtained from Agen Biomedical, Milan,
Italy; Dermatan sulphate (DS) was obtained from Mediolanum Pharm., Milan, Italy, and
Enoxaparin from Rhone-Poulenc-Sante, France.
All low-affinity low molecular weight heparins (LA-LMWHs) and hypersulphated
low molecular weight heparins (sLMWHs) were obtained from Vascular Therapeutics,
Inc., Mountain View, CA. (see Table II) A LMWH fraction with mean MW 5000 was
prepared from unfractionated heparin by nitrous acid depolymerisation. It was then
chemically modified to reduce its antithrombin affinity by an oxidation procedure with
sodium periodate. Aldehydes formed during the oxidation step were reduced with
sodium borohydride to yield primary alcohols. (Young and Hirsh, 1990). N-desulphated
low molecular weight heparin (N-DS-LMWH) was prepared by a solvolytic
desulphation technique, according to the method of Inoue and Nagasawa (Inoue and
Nagasawa, 1976).
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TABLE II : Table showing the series of hypersulphated LMWHs used in the
assays of prothrombinase and intrinsic tenase.
Compounds O-Sulfation Condition Elemental Analysis Estimated # of
sulphate per
disaccharide




































The estimation of degree of sulphation per disaccharide was calculated on the basis of two assumptions :
1. LA-LMWH is composed of a regular disaccharide structure. Each disaccharide has 12 C and X S
2. All samples are pure; there is no organic or inorganic contamination. All sulphur is in sulphate form.
Wt ofC = 12 x 12
WtofS = Xx32
Wt of C /Wt of S = % C / % S
=144 / 32X = C% / S%
so. X = 144 x S% / 32 x C%
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2.2. Methods
2.2.1. Synthesis of Phospholipid Vesicles : Unilamellar phosphatidylcholine-
phosphatidylserine (75%/25%,w/w) vesicles (PCPS) were prepared by modification
of the method of Barenholz et al. (Barenholz et al., 1977)(Bloom et ah, 1979) and
assayed using an inorganic phosphate assay (Ames, 1966), outlined in appendix (ii).
Bovine brain phosphatidylserine (PS) and egg phosphatidylcholine (PC) (3:1
ratio) were measured into a KIMAX glass round bottomed tube (16x150mm) and dried
under a stream of nitrogen. The lipid was resuspended in 5.0 ml of 20mM Tris, 0.15M
NaCl (pH 7.4) and sealed with parafilm under a nitrogen atmosphere. The test tube was
suspended in a Fisher Bath Sonicator, Model #FS14, using a clamp, and sonicated
continuously at 4°C for one hour. The crude vesicles were then centrifuged in a
Beckman Ultracentrifuge with an SW-55 swinging bucket rotor, for 3 hours at room
temperature (150,000 x g). Vesicles were aliquoted from the top 3mls of supernatant
from the centrifugation tube, a fraction shown previously to contain vesicles of a
homogeneous size (Barenholz et al., 1977). An aliquot was saved for phosphate
analysis. For storage, 0.3g sucrose (10% w/v) was added to the vesicles, and following
mixing, aliquots were frozen at -70°C.
2.2.2. Effect ofHeparins on the Activity ofProthrombinase: To examine the effects of
glycosaminoglycans on the activation ofprothrombin by the prothrombinase complex,
the rate of thrombin generation was assayed using a modification of the method of
Barrow et al. (Barrow et al., 1994a). Reactions were performed in 20mM Tris-Cl,
150mM NaCl with 0.1% polyethylene glycol (TSP buffer), pH 7.4. 750pl of a stock
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solution "A" was made : 645pl TSP buffer, 3pl 6mM PCPS vesicles, 6pl 50nM fVa,
90|o,l 20pM prothrombin and 6pl M CaCl2, giving final concentrations of 6pM PCPS
vesicles, 0.2nM fVa, 0.6pM prothrombin and 2mM CaCl2, respectively. Using a
subsampling approach to monitor prothrombin activation, the reaction was initiated by
addition of lOpI InM fXa (final concentration O.lnM) to 50pl of stock "A" and 30pl
TSP buffer. This was performed in the presence of lOpl of glycosaminoglycan, at final
concentrations ranging from 1 -lOOOpg/ml. Two controls were run in parallel, consisting
of 50pl stock "A" and 40pl TSP buffer. Individual lOpl aliquots were removed at 30
second intervals into a 8 x 12 flat-bottomed, 96-well microtitre plate containing lOpl
lOOmM EDTA (final concentration lOmM EDTA), pH 7.4 to quench the activation
reaction. After the final aliquots were removed, the concentration of thrombin in each
well was determined by chromogenic assay, using the thrombin-directed chromogenic
substrate, tGPR-pNA. lOOpl of 200pM tGPR-pNA (final concentration lOOpM tGPR-
pNA), containing 0. lmg/ml polybrene to neutralise the heparin, was added to each well.
The final volume of reactants in each well was 21Opl. Chromogenic substrate hydrolysis
was followed by monitoring the change in optical density every 10 seconds at 22.8°C,
for 5 minutes at 405nm, on a Spectra-max 340 microplate reader (Molecular Devices).
Data Analysis : Rates of chromogenic substrate cleavage were determined using the
manufacturer's software, by determining the slope from the linear portion of the A405 vs
time plot. A standard curve of thrombin activity, with tGPR-pNA, was used to convert
optical density change to thrombin concentration. The rates of activation were calculated
from the slope of the graph of thrombin concentration vs time by linear regression
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analysis (Quattro Pro, version 5.0, Borland International Inc. Scott's Valley, CA).
Comparison with two control reactions lacking glycosaminoglycan, run in parallel, gave
a rate relative to the control. The concentration of glycosaminoglycan that produced
50% inhibition ofprothrombin activation rate (IC50) was calculated to allow comparison
between different glycosaminoglycans. Reactions were performed in duplicate and data
from 3-6 experiments averaged for each analysis.
2.2.3. Mechanism of Inhibition ofProthrombinase by Hypersulphated LMWH : The
susceptibility of individual components of the prothrombinase complex to inhibition by
sLMWH was investigated using a series of assay systems that systematically removed
or substituted individual components of the enzyme complex system. The rate of
prothrombinase activation in the presence of the modified LMWH was studied in the
following buffered systems in the presence of the most potent hypersulphated LMWH,
'S5*.
a) absence of factor V or factor Va
b) absence of phospholipid
c) a system using prothrombin, factor Xa and calcium only (ie. absence of
cofactor and phospholipid)
d) substitution of activated factor V with unactivated factor V
e) a system monitoring the chromogenic activity of fXa
The catalytic advantage associated with the formation of the prothrombinase catalyst is
well documented in the literature (Nesheim, 1984)(Mann, 1987). To maintain
approximately equivalent rates of activation, concentrations of the individual reactants
39
were increased individually, and the final conditions used are given below :
CONDITIONS
complete prothrombinase fXa/fVa/PCPS/II/Ca2*: II 1.2pM, CaCI24mM, PCPS 12pM, fVa 0.24nM, fXa lnM
a. system devoid of cofactor : fXa/ Ca2+/ PCPS / II: II 1.2pM, fXa lOOnM, PCPS 12pM, CaCI24mM, no fWVa
b. system devoid of phospholipid : fXa/ fVa/ II / Ca2+ : II 1.2pM, no PCPS, CaCI2 8mM, fVa 12nM, fXa lOnM
c. system devoid of phospholipid, cofactor and calcium : fXa/ II : II 1.2pM, fXa lOOnM
d. system substituting activated cofactor by unactivated cofactor :
fXa/fV / PCPS / II / Ca2+: II 1.2pM, CaCI2 4mM, PCPS 6pM, fV 8nM, fXa 0.2nM
e. system monitoring the chromogenic activity of fXa : fXa/ S2222 : fXa lnM, 200pM S2222
The rate of generation of thrombin in systems (b) and (c) remained slow despite
increases in reaction concentrations, and subsampling was carried out at 15 and 30
minute intervals to allow determination of the rate of thrombin generation.
2.2.4. Effect ofHeparins on the Activity ofIntrinsic Tenase :
The effect of sLMWH on the activity of intrinsic tenase was determined using a similar
discontinuous assay to the assay of prothrombinase activity outlined in Section 2.2.2.
The rate of fXa generation was determined by modification of the method ofBarrow et
al.,(Barrow et al., 1994a) initially using the fXa-directed chromogenic substrate, S2222,
and subsequently, Chromozym.X. The reactions were initiated by addition of the
substrate, fX. A stock solution "B" was made as follows : 702pl TSP, 6pl 6mM PCPS,
6pl M CaCl2, 6pl 200nM fVIII and 30pl 200nM fIXa. (Final reactant concentrations :
PCPS 24pM,CaCl2 4mM, fVIIIa 0.4nM,fIXa 4nM). 70pl lOOnM a-thrombin (final
concentration lOnM thrombin) was added for exactly 60 seconds at room temperature.
50pl of Stock "B" was then added to 30pl TSP buffer in the presence of lOpl of
glycosaminoglycan (in final concentrations ranging from 0.01 pg/ml to lOpg/ml). Two
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controls were run in parallel, consisting of 50pl Stock "B" and 40pl TSP. The reaction
was initiated by the addition of lOpl 3pM fX (final concentration, 300nM fX). A
subsampling technique was used as described in Section 2.2.2. After the final aliquots
were removed, the concentration of fXa in each well was determined, initially using the
fXa-directed chromogenic substrate, S2222, and subsequently using the substrate,
Chromozym X. Chromogenic substrate hydrolysis was monitored as before.
Experiments were repeated using a variety of glycosaminoglycans.
Data Analysis: Data was analysed as in prothrombinase assay (Section 2.2.2), and
specifically required the determination of a standard curve of fXa activity with the
chromogenic substrate, S2222.
2.2.5. Mechanism ofInhibition ofIntrinsic Tenase by HypersulphatedHeparins:
The mechanism of inhibition of intrinsic tenase was studied using an analogous set of
assays to those outlined in Section 2.2.3 for prothrombinase. Individual components of
the enzyme complex system were systematically removed or substituted, and the rates
of fXa generation were studied in the following buffered systems in the presence of
hypersulphated LMWH
a) absence of fVIIIa or fVIII.
b) absence of PCPS vesicles.
c) a system using fX, flXa and calcium only (ie. absence of fVIII/VIIIa and
phospholipid)
d) chromogenic activity of flXa with Pefachrom.IXa.
e) substitution of activated fVIII by unactivated fVIII.
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CONDITIONS
(full intrinsic tenase): flXa / fX / PCPS /Ca2+/ fVIIIa : CaCI2 4mM, X 300nM, PCPS 24jiM, IXa 4nM, Villa
0.4nM
a) no cofactor : fTXa / fX /PCPS / Ca2+ : CaCI2 2mM, X 400nM, PCPS 19.6nM, IXa ljiM
b) no PCPS : fIXa/ fX / Ca2+/ fVIIIa : CaCI2 4mM, X 300nM, no PCPS, Villa 16nM (Ila 8nM), IXa lfi.M
c) no PCPS, no cofactor : flXa/ fX / Ca2+ : CaCI2 8mM, X 400nM, IXa l^iM, no PCPS, no VIII or Villa
d) chromogenic activity of fIXa : fIXa/ ChZ.Th : fIXa lfiM
c) substitution of activated cofactor for unactivated cofactor : fIXa/ IX/ PCPS / Ca2+/ IVIII : CaCI2 8mM, fX
300nM, PCPS 16fiM, HXa 16nM, fVIII 20nM
2.2.6. Effect ofHypersulphatedLMWHon the Catalytic Rate (kcat), (Km), the Michaelis
Constant and the Apparent Dissociation Constant (Kdapp) for Prothrombinase : To
further determine the type of inhibition caused by the hypersulphated LMWHs, the
catalytic rate constant of the enzyme complex (turnover number, kcat), the Michaelis
constant, Km, and the Kdapp were derived kinetically.
2.2.6. a Determination of the Catalytic Rate for Prothrombinase in the Absence and
Presence of Hypersulphated LMWH. The catalytic rate of prothrombinase was
determined by monitoring the rate of thrombin generation in a continuous assay, using
fXa to initiate the reaction.
9pl 1 OpM fVa, 13 5 pi 80pM prothrombin and 36plM CaCl2 weremixed in the presence
of 18pl 6mM PCPS vesicles in TSP buffer to make a stock solution "C". (Final reactant
conditions : II 2.4pM, fVa20nM, PCPS 24pM, CaCl2 8mM, and S2444 400pM) 250pl
of stock"C" was added to 200pl TSP buffer in a 1 x 1cm cuvette, with the addition of
500pl ofS2444. Amagnetic stir barwas used throughout the procedure. Whilst reactants
were being assembled, a baseline reading was carried out for 30 seconds. The reaction
was initiated following the addition of 50pl lOnM fXa, (final concentration 0.05nM)
giving a final volume of 1 ml in the reaction chamber. The rate of thrombin generation
was determined by monitoring the change in optical density at 405nm for 15 minutes on
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a Beckman DU 7400 spectrophotometer. A standard curve of thrombin activity with
S2444 was used to convert optical density change to thrombin concentration. S2444 was
the chromogenic substrate of choice for this assay, as its reduced efficiency with
thrombin allowed monitoring of thrombin at high rates of activation. In addition, the
reactivity of this chromogenic substrate with thrombin was not inhibited by heparin.
A series of assays were carried out spectrophotometrically to determine the
turnover number under different experimental conditions. Variables examined included
changes in final reactant concentrations, the type of chromogenic substrate, the
temperature ofthe reaction and pre-soaking of the reaction chamber with 1% Tween for
24 hours prior to use. Changes in these variables cause variation in the turnover numbers
quoted for prothrombinase in the literature (Krishnaswamy, 1990). The effect on the
catalytic rate of prothrombinase was noted and optimal conditions were chosen for
subsequent determination of kinetic parameters.
The assay was adapted for use on a Spectra-max 340 microplate reader by using a
smaller volume of reactants. 125pl of stock solution "D" was made consisting of lpl
10pM fVa, 15pl 80pM prothrombin, 4pl M CaCl2, 2pl 6mM PCPS, and 103pil
TSP.(These conditions gave the same final reaction conditions of prothrombin 2.4pM,
fVa 20nM, PCPS 24pM and CaCl2 8mM). 50pl of stock "D" was added to 30pl TSP
buffer and lOpl glycosaminoglycan, or to 40pl TSP for the control reading. 90pl 4mM
S2444 (final concentration 400pM S2444) was added, and the reaction was initiated
using lOpl 0.5nM fXa (final concentration 0.05nM fXa) giving a final volume of200pl
in the reaction well. Readings were taken every 11 seconds for 15 minutes, at 405nm,
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at room temperature. The turnover number was determined in the absence and presence
ofan increasing range ofhypersulphated LMWH (final concentrations of0-1 OOOpg/ml).
Data Analysis : For both techniques, A405 values were imported into a spreadsheet
(Quattro.Pro (version 7.0) Borland Int. Inc., Scotts Valley, CA), point to point slopes
determined, and by reference to the standard curve generated for thrombin activity vs
[S2444], converted to thrombin concentration, and then plotted vs time to obtain the
activation rate. Data was then imported into Table Curve, Jandel. version 4.0, (San
Rafael, CA), and a curve fitted to the graph of kcat(nMIIa/sec/nMXa) vs concentration
of GAG (pg/ml), allowing determination of the IC50 value.
2.2.6.b. Determination of the Michaelis Constant (Km) for Prothrombinase:
The Km, a measure of the relative affinity of the fVa/fXa complex for the substrate,
prothrombin, was determined by measuring thrombin generation in a series of assays
with fixed concentrations of enzyme and cofactor, and increasing substrate
concentrations.
Simultaneous assays were performed in the absence and presence of sLMWH as
follows:-
A series of nine stock solutions were made, each of final volume 125pi, consisting of
fixed concentrations of fVa, PCPS and CaCl2, and increasing concentrations of
prothrombin (Final concentrations : 20nM Va, 24pM PCPS, 8mM CaCl2, prothrombin
ranging from 0 - 3.75pM).
Each stock contained lpl lOpM fVa, 2pl 6mM PCPS and 4pl M CaCl2, and 15pl of
3pM - 125pM prothrombin. 50pl of stock was mixed with 40pl Tris-PEG buffer in a
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series of wells and 90pl 4mM S2444 added (final concentration 400pM S2444). 20pl
0.5nM fXa (final concentration 0.05nM) was added to each well using a multichannel
pipette to initiate the reaction, giving a final volume of200pl. Changes in optical density
at 405nm were monitored for 15 minutes on a Spectra-max 340 micro-plate reader at
room temperature, and converted to the thrombin generation rate. Assays were carried
out simultaneously in the presence of 10gl lOmg/ml sLMWH, giving a final
concentration of 500pg/ml. Assays were performed in duplicate.
Data Analysis: Km and Vmax were determined by importing data into Table Curve, and
fitting the data for the thrombin generation rate vs prothrombin concentration ([II]) to
the equation (Chang et al., 1997)
y_ [II\xVmax ^ ^ Vmax
Km + [If\ ancj [limiting reactant\
2.2.6.C. Determination of Kdapp for Prothrombinase, by Increasing the Cofactor
Concentration, in the Absence and Presence ofsLMWH: The apparent Kd of fVa for
prothrombinase, at saturating concentration of PCPS vesicles, was determined by
measuring the rate of thrombin generation a series of assays with fixed substrate and
enzyme concentrations, and increasing concentrations of cofactor.
A series of eleven stock solutions were made. Each stock had a final volume of 125pl
and contained 15pl 80pM prothrombin, 4pl M CaCl2 and 2pl 6mM PCPS vesicles (final
concentrations ofprothrombin 2.4pM, CaCh 8mM, and PCPS 24pM), with l-4pl 1 pM
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fVa (final concentration 2-8nM fVa), and l-5pl lOpM Va (final concentration 10-
lOOnM fVa). A control experiment contained no fVa.
50pl of each stock was mixed with 40pl Tris-PEG buffer in a series of wells. 90pl
400pM S2444 (final concentration of 400|iM S2444) was added, followed by 20pl
0.5nM fXa (final concentration 0.05nM) using a multichannel pipette, to initiate the
reaction, giving a final volume of200pl. The thrombin generation rate was determined
as in Section 2.2.6. Assays were carried out simultaneously in the presence of 1 Omg/ml
sLMWH, giving a final concentration of 500pg/ml, and were performed in duplicate.
In an analogous assay, the Kdapp of fXa for prothrombinase was determined by
measuring the turnover rates by varying the concentrations of fXa from 0-25nM.
Data Analysis : Data was fitted to a second order polynomial equation aO + al*t + a2*t2.
The a2 coefficient gives the rate of change in A405 and is equal to
k-S2444 * kII*[Xa/Va]/2
where k-S2444 is the rate that fXa cleaves S2444. The thrombin generation rate was
plotted against concentration of fVa, and the affinity of fVa for fXa determined by
fitting the data to the equation (Krishnaswamy, S., 1990):-
Xa-Va=b = [(Valt+Xalt+kd)±<J(Valt+Xa}t+k(f)2-4Xalt+Valt)\l2
rate — kb
2.2. 7 Determination of the Kinetic Parameters for Intrinsic Tenase:
In an analogous series of assays, the catalytic rate (kcat), the Michaelis (Km)
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constant, and the apparent dissociation constants (Kd) for enzyme, were determined for
intrinsic tenase, in the absence and presence of sLMWH. The final reactant
concentrations used for determination of the turnover number were :
fX:192nM fVIIIa 0.48nM fIXa 2.5nM PCPS 40pM fIXa 2.5nM
ChZX 500pM
Full methodology is given in appendix (iii). The critical differences in methodology
from the prothrombinase assays involved are:
(i) the prior activation of fVIII by thrombin, yielding a fVIII/VIIIa/thrombin mixture to
either initiate, or participate in the intrinsic tenase reaction.
(ii) the initiation of the reaction with the substrate, fX.
2.2.8. Effect ofHypersulphatedLMWH on Prothrombinase and Intrinsic Tenase, using
Isolated Washed Platelets as the Membrane Surface. Synthetic PCPS vesicles (75:25)
do not fully mimic the platelet surface (London and Walsh, 1996)(Bevers et ah,
1982)(Rawala-Sheikh et al., 1990). To determine whether hypersulphated LMWHs exert
different inhibitory effects in the presence ofa platelet surface in place ofPCPS vesicles,
a series of continuous assays of prothrombinase and intrinsic tenase were carried out
using an isolated washed human platelet preparation, in the presence and absence of
sLMWH.
Isolation and Activation of Platelets: Platelets were isolated by modification of the
procedure of Mustard et al. (Mustard et al., 1972)(Nesheim et al., 1988). Human blood
was drawn from healthy volunteers and added to 3.2% sodium citrate (10:1, v/v), using
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a 0.6mm gauge needle, and mixed gently without agitation. Platelet-rich plasma (PRP)
was prepared by centrifugation at 190 x g for 15 minutes at 37°C. PRP was then
removed and the platelets were pelleted by centrifugation at 2500 x g for 15 minutes at
37°C. The supernatant plasma was removed, and the platelets were resuspended in
Tyrode's modified buffer (TMB) + Na Citrate (10ml) + PGE, (5pM), and incubated at
37°C for 15 minutes. Tyrode's buffer was prepared as described in the procedure by
Yuan et al.(Yuan et al.,1996). The suspension was recentrifuged at 1200 x g for 10
minutes, resuspended in a solution of the same composition, and incubated for 10
minutes at 37°C. The procedure was repeated, but following the next centrifugation, the
pellet was resuspended in TMB 2ml (no Na citrate) and kept at 37°C until use. The
number of cells present were counted using a haemacytometer slide, as shown in
appendix (v). The washed platelets were retained at 37°C and used within 2 hours of
isolation. Immediately prior to use, platelets were activated using lOpM A23187. All
steps were performed in plastic containers, and all operations involved in isolating and
washing the platelets were carried out at 37°C. Assays of prothrombinase and intrinsic
tenase were carried out under the following conditions, using the methodology outlined















platelets lOpl of suspension containing 1.7 x 10g cells
2.2.12. Plasma-based Coagulation Assays
Activated Partial Thromboplastin Time : The Activated Partial Thromboplastin Time
(APTT) is a screening test for the intrinsic and common coagulation pathways, and tests
factors II, V, VIII, IX, XI, XII, prekallikrein (PK) and high molecular weight kallikrein
(HMWK). (Proctor and Rapaport, 1961) It acts as a suitable measure of the activities of
the intrinsic tenase and prothrombinase complexes in plasma assays. APTTs were
carried out using the ST4 coagulometer, and the APTT reagent used was Thrombosil
(Ortho Diagnostics, NJ.), a commercial reagent containing rabbit brain phospholipid
extract with a micronised silica activator. 50pl of sample (normal plasma pool, or
plasma immunodepleted of antithrombin) (Affinity Biological Inc.,Ontario) was added
to 50pl Thrombosil and incubated for 5 minutes. 50pl CaCl2 was added, and the
machine timer was started. Results were recorded in seconds.
Factor Xa-Clotting Time : The fXa-clotting time is a screening test that measures the
activation of prothrombin to thrombin and is sensitive to the levels of fV and
prothrombin. It was used as a measure of prothrombinase activity. The procedure was
carried out on an ACL 3000 centrifugal coagulation analyser. 0.02M CaCl2 was added
to fXa/phospholipid reagent (0.1 % BSA/Cephalin solution, 1 ul 1.58mg/ml fXa), and the
reagent placed in a well containing normal plasma, or plasma immunodepleted of
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antithrombin. The time for clot formation was monitored using the PT mode of the
coagulation analyser.
Note : The experiments outlined in Section 2.2.12 were performed by M. Johnson,
A.R.T., Hamilton Civic Hospitals Research Centre, Hamilton, Ontario.
2.3. Statistical Analysis
All experimental values for IC50 reported in sections 2.2.2-5 and 2.2.8 represent the
mean of 3-6 experiments performed in duplicate.
Mean and standard deviation were calculated using Quattro Pro. version 5.0 (Borland
International, Inc., Scotts Valley, CA).
The correlation between mean IC50 values for prothrombinase and intrinsic tenase, and
the degree of sulphation of LMWH was determined by using a test of rank correlation
(Pearson) and also by one-way analysis of variance (ANOVA). Statistics were derived
using Minitab, 1996. A value of p< 0.05 was considered statistically significant.
Experimental values for kinetic parameters in Sections 2.2.6 and 2.2.7 were carried out
in duplicate, and are given in full with mean Km and Kdapp values, and their associated
standard deviation.
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CHAPTER 3 : RESULTS
3.1. Effect of Hypersulphated LMWH on the Activity of Intrinsic Tenase and
Prothrombinase :
Inhibition of Intrinsic Tenase Activity by sLMWH : To investigate the structural
requirements for the inhibition of LMWH, LA-LMWH was first N-desulphated by a
solvolytic desulphation technique (Inoue and Nagasawa, 1976). In an assay of intrinsic
tenase activity, at fixed concentrations of fIXa, fVIIIa, fX and PCPS vesicles, LA-
LMWH produced 50% inhibition of the initial velocity of fX activation at 16.3pg/ml.
A LMWH with normal antithrombin affinity inhibited intrinsic tenase to the same
extent, with an IC50 value of 13.2pg/ml (see Table III). In contrast, N-desulphated
LMWH had less inhibitory effect, with a 10-fold increase in the IC50 value to 166pg/ml.
These findings indicate that the inhibition of intrinsic tenase by LMWH is antithrombin-
independent, but charge-dependent.
To further investigate the charge-dependent effect, LA-LMWH was progressively
hypersulphated using sulphur trioxide as a sulphate donor. Table II ( see "Experimental
Methods") shows the estimated degree ofsulphation for each LMWH. In contrast to LA-
LMWH, the most highly sulphated LMWH, "S5", was a 32-fold more potent inhibitor
of intrinsic tenase with an IC50 value of 0.47pg/ml. These results are shown graphically
in figure 10. In conclusion, progressive hypersulphation of LMWH increases the
inhibitory potency ofthe glycosaminoglycan, reflected by a progressive reduction in IC50
values. These results, when subjected to regression analysis, gave a Pearson correlation




Figure 10 : Inhibition of Intrinsic Tenase by sLMWH.
Glycosaminoglycans were added at the given concentrations and the initial velocity
of the activation of 300nM fX by intrinsic Xase (4nM fIXa, 400pM fVIIIa, 24pM PCPS)
was determined at room temperature. The ordinate is expressed as the rate relative to
the mean of 2 control readings carried out in the absence of glycosaminoglycan. Under
similar reactant conditions, a turnover number ofl7.9nM Xa/s/nM Villa was obtained.
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< 0.001, indicating that the potency of LMWH depends highly on its degree of
sulphation. Mean IC50 results are given in Table III.
Inhibition ofProthrombinase Activity by sLMWH : The inhibitory effect of our series
of hypersulphated LMWHs was examined on prothrombinase activity to determine if
a charge-dependent inhibitory effect similar to that seen with intrinsic tenase was
present. The results of these assays were expressed as mean IC50 values and are
summarised in Table III.
Unfractionated heparin had no detectable effect on prothrombinase function at
concentrations up to lOOOpg/ml (see figure 11), consistent with the results of Barrow et
al. (Barrow et al., 1994a). Likewise, no inhibitory effect was demonstrated for either
LA-LMWH or Enoxaparin. In contrast, hypersulphated LMWH is a potent inhibitor of
prothrombinase. Similar to the inhibitory effects demonstrated in intrinsic tenase assays,
by increasing the degree of sulphation of LMWH, there is a progressively greater
inhibition of prothrombinase, as reflected by a steady reduction in the IC50 value (see
figure 12).
Linear regression analysis gave a Pearson correlation coefficient of -0.92, and one¬
way ANOVA gave a p value < 0.001, indicating a very highly statistically significant
correlation between the degree of sulphation and the mean 1C50 values.
5*
Table III: Effect of a Series ofHypersulphated Low Affinity LowMolecular
Weight Heparins on Intrinsic Tenase and Prothrombinase : This table shows
the series of LMWHs used in this study. LA-LMWH was N-desulphated by a
solvolytic technique. LA-LMWH was also hypersulphated by a technique using
sulphur trioxide as a sulphate donor. Results from assays of prothrombinase and
intrinsic tenase activity show that as the degree of sulphation increases, the
inhibitory potency of LA-LMWH increases, reflected by progressive reduction
in IC50 values.









N-desulphated LMWH 1.7 >1000 166 ±25
LMWH (Enoxaparin) 2.3 >1000 13.2 ±7.7
LA- LMWH 2.42 >1000 16.3 ±6.1
LA- LMWH SI 2.49 560 ±22.4 7 ± 3
LA- LMWH S2 2.88 550 ±148 4± 1.4
LA- LMWH S3 3.03 250 ±40.8 4.25 ± 1.97
LA- LMWH S4 3.82 79 ± 11.6 0.25 ±0.09
LA- LMWH S5 3.9 30 ± 16.3 0.47 ±0.2
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Figure 11 : Inhibition of Prothrombinase by sLMWH.
The ordinate axis shows the rate relative to the mean of 2 controls.
Unfractionated heparin ( • ), low affinity LMWH (LA-LMWH) ( ■ ),
and 2 hypersulphated LMWHs, S4 (▼), and S5 (♦) were added at the
indicated concentrations, and the initial velocity of the activation of 1.2pM
human prothrombin by prothrombinase (InM fXa, 0.24nM fVa, 24pM PCPS,
4mM Ca++ ) was determined at room temperature.
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Figure 12 : Effect of Increasing the Degree of Sulphation of LMWH on
IC50 for Prothrombinase
The ordinate axis shows the concentration of glycosaminoglycan which causes
50% inhibition of the initial velocity of prothrombin activation (IC50, pg/ml).
Neither N-desulphated LMWH, nor LA-LMWH have an inhibitory effect on
prothrombinase.
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The IC50 values for the LMWH series were 2 orders ofmagnitude higher than those
for intrinsic tenase, indicating that the most potent inhibitory effect of these hypersulphated
LMWHs is on the intrinsic tenase complex.
In conclusion, progressive hypersulphation of LMWH increases the degree of
inhibition of both enzyme complexes, and the inhibition of the intrinsic tenase and
prothrombinase complexes by LMWH in buffer systems is charge-dependent.
3.2. Effect ofHypersulphated LMWH on Plasma-Based Coagulation Assays :
Coagulation assays were performed to demonstrate whether the results observed in
buffer systems occur in plasma systems. The activated partial thromboplastin time (APTT)
was used as a measure ofboth intrinsic tenase activity and prothrombinase activity, and the
fXa-clotting time was used as a measure of prothrombinase activity.
Whilst unfractionated heparin at therapeutic concentrations had no effect on the APTT
and fXa-clotting time in plasma immunodepleted of antithrombin, low affinity,
hypersulphated LMWH prolonged the APTT and fXa clotting time in AT-depleted plasma
to the same extent as in control plasma (see figures 13 and 14). These results demonstrate
that sulphation of LMWH effects inhibitory properties in prothrombinase and intrinsic
in plasma systems, and confirms that the mechanism of inhibition is antithrombin-
independent.
3.3. Mechanism of Inhibition of Prothrombinase and Intrinsic Tenase by sLMWH:
As prothrombinase and intrinsic tenase are complex multicomponent systems, it
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sLMWH (pg/ml) Heparin (U/ml)
Figure 13 : Effect of hypersulphated LMWH (sLMWH) or heparin on the
activated partial thromboplastin time (APTT) in control plasma (• ) or
plasma immunodepleted of antithrombin. (■ ) 0.1 U/ml is equivalent to
0.5pg/ml heparin.)
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Figure 14 : Effect of hypersulphated LMWH (sLMWH) or heparin
on the factor Xa clotting times in control plasma (•) or plasma
immunodepleted of antithrombin. (■)
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was possible to determine rates of activation under conditions where individual reactants
were systematically removed or substituted. The influence of hypersulphated LMWH on
the partially reconstituted activation complexes was used to reveal the component(s)
responsible for glycosaminoglycan sensitivity. Figures 15 and 16 show the effects of the
most highly sulphated LMWH, 'S5', on different combinations of reactants in
prothrombinase and tenase systems, respectively. This particular hypersulphated LMWH
was chosen as it demonstrated potent inhibitory effects on both intrinsic tenase and
prothrombinase activity (see Table III).
A similar pattern of inhibition by LMWH "S5" was demonstrated in both
prothrombinase and tenase systems. In systems consisting of the fully assembled enzyme
complexes, a dose dependent inhibitory effect was present. In systems devoid of
phospholipid, inhibitory effects were also evident in assays of tenase and prothrombinase,
and similar IC50 values were found to those obtained with the complete enzyme complex.
The IC50 for the effect ofLMWH 'S5' on the full prothrombinase complex was 30pg/ml, and
was unchanged in a system devoid ofphospholipid. For intrinsic tenase, the IC50 ofLMWH
was 0.4pg/ml, and for a system devoid of phospholipid was 0.5pg/ml. These findings
indicate that the inhibitory effect is not phospholipid-dependent.
In systems devoid of cofactor alone (either fV/VIII or fVa/VIIIa), LMWH "S5"
showed no inhibitory effect. For prothrombinase, it was possible to monitor thrombin
generation in a system devoid of cofactor and phospholipid, as well as in a system devoid
of cofactor, phospholipid and calcium; no inhibitory effect was seen in either system. For
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Figure 15 : Mechanism of Inhibition ofProthrombinase by sLMWH :
sLMWH 'S5' was added at the indicated concentrations and prothrombinase
activity was determined in a series of buffer systems in which individual
components of prothrombinase were substituted or removed.
Final reactant conditions are given in Section 2.2.3.
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Figure 16 : Mechanism of Inhibition of Intrinsic Tenase by sLMWH :
sLMWH 'S5' was added at the indicated concentrations and the activation of
fX was determined in a series of buffer systems in which individual components
of tenase were substituted or removed. Final conditions for each system are given
in Section 2.2.5.
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intrinsic tenase, despite increases in reactant concentrations, rates of activation remained
slow in a system devoid of fVIII and PCPS, and were unmeasurable in a system devoid of
factor VIII, PCPS and calcium; in the latter system, even prolonged incubation of 3 hours
failed to reveal any activation of fX (400nM) by fIXa (lpM).
In systems involving the substitution of non-activated for activated cofactor (fV or
fVIII in place of fVa or fVIIIa), an initial lag phase was seen on graphs of thrombin and fXa
generation vs time, reflecting the positive feedback effect of thrombin and fXa on fV or
fVIII activation, respectively. The linear part of the graph was analysed to give an apparent
rate of activation. Results showed a similar inhibitory effect to buffer systems using fVa or
fVIIIa, indicating that activation of the cofactors have taken place. By inference, this
suggests that the inhibitory steps are not occurring at the stage of cofactor activation.
For both systems, the effects ofhypersulphated LMWH on the chromogenic activity
of the enzymes were also examined. For prothrombinase, the effect of LMWH "S5" on the
hydrolysis of the chromogenic substrate, S2222, by fXa, showed no evidence of inhibition.
With the system involving hydrolysis of Pefa IXa/60% ethylene glycol by fIXa
alone, hypersulphated LMWH caused minor inhibition. Flowever, the latter assay was of
limited value since fIXa has virtually negligible activity with chromogenic amide substrates
(Stiirzebecher et al., 1997a)(Stiirzebecher et al., 1997b)(Bode et al., 1997)(Brandstetter et
al., 1995).
It is apparent that to maintain similar rates of activation, each system required
differing final reactant concentrations and sampling times. However, the fact that similar
64
IC50 values were obtained with or without phospholipid suggests that the effect of S5 was
not limited to only the fully assembled activation complexes. This legitimises the approach
of studying incompletely assembled activation complexes. Taking this into account, both
intrinsic tenase and prothrombinase complexes show a phospholipid-independent, cofactor-
dependent mechanism of inhibition by hypersulphated LMWH.
3.4. Determination of Mechanism of Inhibition by Kinetic Parameters :
Since the previous results suggest that hypersulphated LMWH disrupts assembly of
the activation complexes, it was of interest to determine the mechanism of inhibition by
detailed kinetic analysis. This is warranted because complex assembly affects both the k^,
and Km ofprothrombinase (Mann, 1987)(Nesheim, 1984)(Rosingetal., 1980). The increase
in kcat in both prothrombinase and intrinsic tenase has been attributed to the effect of the
cofactor, whereas the phospholipid component of the enzyme complexes is responsible for
the Km effect. Thus, the turnover number, kcat and the Michaelis constant, Km, of the
fXa/fVa complex for prothrombin, and of the fIXa/fVIIIa complex for fX were determined
kinetically, in the presence of a saturating concentration of phospholipid (24-50pM), and
in the absence or presence of hypersulphated LMWH.
Determination of the Turnover Number for Prothrombinase Under Changing Reactant
Conditions: Prothrombinase activity wasmonitored under a series ofdiffering experimental
conditions to determine the optimal assay conditions for the determination ofKm and kcat
values. Results are summarised in Table IV.
TableIV:Summaryofthe"turnov rnumber"de iv dfr spectrophotometricassaysro hrombinaseac vitycarr d outunderaseri sfvaryingexperimentalco ditio .Thturnov rnumbegiv ni p n8co s st ntw thlu squo d


























































































































A turnover number of 21s"1 was obtained in a spectrophotometric assay of
prothrombinase, under the conditions outlined in panel 8 in Table IV, a value consistent
with those quoted in the literature under comparable conditions (Krishnaswamy, 1990b).
At room temperature, and under the same final reactant conditions, a turnover number
of 13 s'1 was obtained (panel 4, Table IV).
For practical reasons, the assay was adapted for use in the plate reader by
adjusting the final volume . Turnover numbers of 13.8s"1 and 12s"1 were obtained under
the same conditions (fVa 20nM, fXa 0.05nM, II 2.4pM, PCPS 24pM, calcium 8mM,
S2444 0.4mM) for plate reader and spectrophotometric analysis, respectively.
Turnover numbers, expressed with respect to the limiting reactant component,
were determined in the absence and presence of increasing concentrations of sLMWH
(see figure 17a). A dose-dependent inhibitory effect was evident, and showed a pattern
consistent with the inhibitory effect seen in earlier discontinuous assays. The IC50 value
was found to be 226pg/ml, consistent with an IC50 value of 300pg/ml determined in a
discontinuous assay. At concentrations ofup to 1 OOOpg/ml, thrombin generation was not
completely inhibited. Higher sLMWH concentrations were not examined as there was
the possibility of precipitation of glycosaminoglycan with chromogenic substrate.
Determination ofthe TurnoverNumberfor Intrinsic Tenase at Increasing Concentrations
of sLMWH : A turnover number of 17.9nM Xa/sec/nMVIIIa for intrinsic tenase was
obtained at room temperature using a plate reader assay, in the absence of sLMWH. This
result is consistent with reported turnover numbers determined under similar experimental
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conditions in the literature (Chang et al., 1997).
With increasing concentrations of sLMWHs, a dose-dependent inhibitory effect was
evident, and an IC50 value of 0.37pg/ml was determined; this value is in agreement with an
IC50 value of O.lpg/ml determined in a discontinuous assay. At concentrations of over
lOpg/ml of sLMWH, the rate of generation of fXa was almost completely inhibited (see
figure 17b).
In conclusion, these continuous assays ofprothrombinase and intrinsic tenase have
demonstrated a dose-dependent inhibitory effect of the sLMWH, consistent with potencies
seen in earlier discontinuous assays. In addition, in the presence of increasing concentrations
of sLMWH, a differential inhibitory effect is seen, with almost complete inhibition of fXa
generation.
Determination ofthe Km for Prothrombinase and Intrinsic Tenase :
The Michaelis constants for prothrombinase, and for intrinsic tenase, ameasurement
ofthe affinity of the substrate towards the enzyme complex, were determined bymeasuring
the turnover numbers at a range of increasing substrate concentrations. The mean, standard
deviation and individual Km values for duplicate assays in the absence and presence of
500pg/ml V20S (prothrombinase) and 0.25pg/ml and 0.5pg/ml V20S (intrinsic tenase) are
shown in Table V, and the results for representative assays are shown in figures 18a and
18b.
For prothrombinase, in the presence of 500pg/ml sLMWH, the k<.at was reduced by


































PANEL A : Effect of sLMWH on the Turnover Number for Prothrombinase.
Turnover numbers were determined at the given concentrations of sLMWH.
(2.4pM II, 0.05nM fXa, 20nM fVa). A dose-dependent inhibitory effect was seen.
PANEL B : Effect of sLMWH on the Turnover Number for Intrinsic Tenase
Turnover numbers were determined at the given concentrations of sLMWH, under
following conditions: fX 192nM, fIXa 2.5nM, fVIIIa 0.48nM, PCPS 24pM)
A dose dependent inhibitory effect was present, and at concentrations of lOpg/ml,
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Figure 18 :
PANEL A : Determination of Km for Prothrombinase in Absence or Presence of sLMWH.
The Km for prothrombinase was determined by measuring the turnover number, expressed as
nMIIa/s/nM Xa, at a range of increasing substrate concentrations, in the absence ( • ) and the
presence ( ■ ) of 500pg/ml sLMWH. This graph represents the results of a single assay. The Km
remains unchanged in the presence of sLMWH, and kcal is reduced 3-fold.
PANEL B : Determination of Km for Intrinsic Tenase in Absence or Presence of sLMWH.
The Km for intrinsic tenase was determined by measuring the turnover number, expressed
as nMXa/sec/nMVIlla, at a range of increasing substrate concentrations, in the absence (•)
and presence (■) of 0.25pg/ml sLMWH. This graph shows turnover numbers and derived Km
values for a single assay. The Km is relatively unchanged and the k is reduced 3-fold.
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TABLE V : Km VALUES for PROTHRQMBINASE and INTRINSIC TENASE
This table shows the absolute Km values for duplicate assays ("assay 1" and
"assay 2") of prothrombinase (II 2.4pM, fVa 20nM, fXa 0.05nM, PCPS 24pM,
CaCl2 8mM, S2444 400pM) expressed in pM, and for intrinsic tenase (fX 192nM,
fVIII/VIIIa 0.48nM, CaCl2 8mM, flXa 2.5nM, ChZX 500pM), expressed in nM.
Assays were performed in the absence and presence of the given concentrations of
sLMWH.
1. Km Values for Prothrombinase Assays :
no sLMWH 500pg/ml sLMWH
'assay 1 assay 2 assay 1 assay 2
Km (pM) 0.2 0.1 0.21 0.1
Vmax (nM Ila/s/nM Xa) 7.8 4.3 2.4 2.0
mean Km 0.15|jM mean Km 0.15pM
SD 0.05 SD 0.05
2. Km values for Intrinsic Tenase Assays :
no sLMWH 500pg/ml sLMWH
assay 1 assay 2 assay 1 assay 2
Km (nM) 32.9 23.9 71.5 48.7
Vmax (nM Ila/s/nM Xa) 16.0 15.3 2.0 5.4
mean Km 28.4nM meanKm60.1nM
SD 4.5 SD 11.4
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(kcat/Km) was reduced from a value of39M"'s"' to According to Michaelis-Menten
kinetics, this pattern is consistent with a noncompetitive mechanism of inhibition. A similar
pattern of inhibition was seen with intrinsic tenase; in the presence of 0.5pg/ml sLMWH,
kcat was reduced 8-fold, and the Km increased minimally from 28 to 60nM. The catalytic
efficiency was reduced from a value of 0.56 M"'s"' to 0.07 NT's"1. These results are
consistent with the noncompetitive inhibitory effect of unfractionated heparin on intrinsic
tenase, demonstrated by Barrow et al.(Barrow et al., 1994a).
With minimal changes in Km, and relatively greater effects on k^,, it was important
to determine the way in which the cofactor influences the enzyme complex in the presence
of hypersulphated LMWH, and, for this reason, the effect of sLMWH on the apparent
dissociation constant, Kdapp of fVa for prothrombinase was determined. The Kdappof the
enzymes, fXa for prothrombinase , and fIXa for intrinsic tenase were also determined.
Determination ofKdapp ofenzyme and cofactor to prothrombinase and intrinsic tenase:
The Kdapp of fVa for prothrombinase was determined kinetically by monitoring the
concentration dependence ofcofactor on substrate activation, in the presence ofa saturating
concentration of phospholipid. In the presence of 500pg/ml sLMWH, the Kdapp of fVa for
prothrombinase increased from a mean value of 1.18nM to 9.96nM, and in an analogous
experiment, determination of the Kdapp for fXa, determined by monitoring the concentration
dependence ofenzyme on substrate activation, also increased, from a mean value of0.18nM
to 4.7nM (see Table VI, and figures 19a and b).
The Kdapp of flXa for intrinsic tenase was determined in an analogous set of assays, and
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TABLE VI : SUMMARY of KINETIC PARAMETERS
Panel 1 shows the absolute Kdapp values (nM) for duplicate assays ("assayl" and "assay2") of fVa for
prothrombinase (II 2.4p.M, fVa 0 - 20nM, fXa 0.05nM, PCPS 24jiM, CaCI2 8mM, S2444 400p.M), and
panel 2 shows the Kdapp values of fXa for prothrombinase (II 2.4pM, fXa 0 - 25nM, fVa 2nM, PCPS
24pM, CaCI, 8mM, S2444 400fiM), in the absence or presence of the given concentration of sLIVTVVH.
The values for the Kdapp of fIXa (nM) for intrinsic tenase (fX 192nM, fVIII/VIIIa 0.48nM, CaCI2 8mM,
fIXa 0 -4nM, ChZX 500p.M), in the absence or presence of the given concentration of sLMWH, are
shown in Panel 3.
1. K.d,rr of fVa towards Prothrombinase :
no sLMWH 500ug/ml sLMWH
assay 1 assay 2 assay 1 assay 2
Kd (nM) 1.77 0.63 11.98 7.34
k„, (nMIIa/s/nM Xa) 4.01 4.52 1.98 2.45
mean Kd : i.2 mean Kd : 9.96
SD : 0.57 SD : 2.32
2. Kd,rr of fXa towards Prothrombinase :
no sLMVVH 500qg/ml sLMWH
assay 1 assay 2 assay 1 assay 2
Kd 0.28 0.09 8.34 1.17
k[lt(nM Ila/s/nM Xa) 2.19 1.24 0.94 0.39
mean Kd: 0.18 mean Kd : 4.75
SD : 0.09 SD: 3.58
3. Kd,rr of fIXa towards Intrinsic Tenase :
no sLMWH 0.25ug/ml sLMWH
assay 1 assay 2 assay 1 assay 2
Kd (nM) 1.93 1.27 3.13 2.8
k„, nMXa/s/nM Villa 17 11.56 4.56 4.7
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Figure 19 :
PANEL A. Determination of Kd of fVa for Prothrombinase in Absence or Presence of sLMWH.
»pp
The Kdapp of flXa for prothrombinase was determined by measuring the concentration dependence
of cofactor, fVa on substrate activation. The graph shows turnover numbers (nMIIa/s/nMXa), at a
range of increasing cofactor concentrations, in the absence (•) or the presence (■) of 500pg/ml. This
graph represents the results of a single assay.
PANEL B. Determination of Kdapp of fXa for Prothrombinase in Absence or Presence of sLMWH.
The Kdapp of fXa for prothrombinase was determined in an analogous set of assays. This graph shows
turnover numbers and derived kcat and Kd parameters for a single assay.
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remained relatively unchanged in the presence of 0.25pg/ml sLMWH (see figure 20).
The interpretation of this data is not clear; an increase in the Kdapp of fVa, and of fXa
towards prothrombinase suggests individually a change in the affinity of enzyme, and of
cofactor, towards the assembled complex in the presence of sLMWH. However, the Kdapp
for intrinsic tenase remains relatively unchanged in the presence of sLMWH.
3.5. Effect ofHypersulphated LMWH on Prothrombinase and Intrinsic Tenase in an
Assay Using Platelets as the Membrane Surface :
Although PCPS vesicles are used experimentally as an analogue of thrombin-
stimulated platelets, for several reasons, synthetic PCPS vesicles do not completely mimic
the platelet surface (London and Walsh, 1996). These include differences in electrostatic
and hydrophobic interactions between cofactor, enzyme and negatively charged lipid
surfaces (Kalafatis et al., 1994)(Gilbert and Baleja J., 1995)(London and Walsh,
1996)(London et al., 1996). Differences also exist in prothrombinase complex assembly
on the two surfaces (Larson et al., 1998). A series of assays were carried out substituting
synthetic isolated washed human platelets for synthetic PCPS vesicles, to determine if this
would influence the potent inhibitory effect already demonstrated on the PCPS vesicle
surface.
In a series of assays of intrinsic tenase activity using both activated (calcium
ionophore, A23187) and non-activated human platelets, a dose-dependent inhibition of fXa
generation was observed (see figure 21a), with a mean IC50 value of 1 pg/ml. In addition, a
dose-dependent increase in the "lag phase" prior to the initiation of the clotting process was
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[IXa] nM
Fig. 20 : Determination of the Apparent Kd for fIXa towards Intrinsic Xase
The Kdapp for flXa towards the assembled intrinsic tenase complex was
determined kinetically by monitoring the concentration dependence of enzyme
on substrate activation. The catalytic rates of intrinsic Xase were determined
in the absence (•) and presence (■) of 0.25pg/ml sLMWH, a concentration
that was higher than the ICgg value.
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observed, starting at a concentration of O.lpg/ml (see figure 21b). For prothrombinase,
using the same isolated activated platelet preparation as in the intrinsic tenase assays, and
in the presence of exogenous fVa, no inhibition was evident. In a repeat set of
prothrombinase assays, where exogenous fVa was omitted (Mast and Broze, Jr., 1996),
inhibition of thrombin generation was seen at sLMWH concentrations of lOOOpg/ml, and
a dose-dependent prolongation of the "lag-phase" was observed, starting at a concentration
of lOpg/ml (see figures 22a and 22b).
These results demonstrate that despite differences in enzyme complex assembly and
catalytic function between synthetic PCPS vesicles and platelets, hypersulphated LMWH
inhibits the activity of prothrombinase and intrinsic tenase on both membrane surfaces.
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log [sLMWH](ng/ml) log [sLMWH] (ng/ml)
Figure 21 : Effect of sLMWH on Intrinsic Tenase in an Assay Substituting PCPS
Vesicles for Isolated Washed Human Platelets.
Figure 'a' shows the effect of sLMWH on the turnover number of intrinsic tenase, at
room temperature and represents the results of a single assay.
Figure 'b' shows the effect of sLMWH on the time to initiate generation of fXa, and
this graph also represents data from one assay.
Figure 22a Figure 22b
Figure 22 : Effect of sLMWH on Prothrombinase in an Assay Substituting PCPS
Vesicles for Isolated Washed Human Platelets.
Figure 'a' shows the effect of sLMWH on the turnover number of prothrombinase,
9
at room temperature. (The conditions were 2.4pM II, 0.05nM fXa, 9.2 x 10 platelets/ml,
no lVa, calcium 4mM). This graph represents the results of a single assay. Figure 'b'
shows the effect on the time to initiate generation of thrombin (sees), and also shows data
from a representative assay.
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CHAPTER 4 : DISCUSSION
The intrinsic tenase and prothrombinase complexes contribute directly to
thrombin generation in the process ofblood coagulation, and as such, are ideal targets
for the inhibition of blood coagulation. Since these multicomponent complexes are
assembled from intrinsic and activated components, there are numerous approaches
available for their inhibition. These include direct inactivation of the enzyme or
disruption of the capacity of the complex to assemble productively. Inhibitors
available to date include active site-blocked factors IXa (IXaj) and Xa (Xa,)(Benedict
et al., 1991; Wong et ah, 1997), anti-flX/IXa monoclonal antibody (Feuerstein et ah,
1997), and active site-directed fXa inhibitors (Tuszynski et ah, 1987; Vlasuk, 1993;
Cappello et al., 1995; Hara et al., 1995; Taniuchi et al., 1998).
Active site-blocked fXa and flXa competitively inhibit prothrombinase and
intrinsic tenase in vitro (Wong, Gunn et al., 1997), and effectively inhibit thrombosis
in several animal models ofvenous (Wong, Gunn et al., 1977) and arterial thrombosis
(Benedict, Ryan et al., 1991)(Benedict, Ryan et al., 1993)(Spanier, Oz et al., 1997).
Active site blocked fXa inhibits the assembly of activated enzyme within
prothrombinase (Nesheim, Kettner et al., 1981)(Skogen, Esmon et al., 1984), and
may also substitute for the substrate, fX within intrinsic tenase. (Benedict, Ryan et
al., 1993).
BC2, a murine anti-flX/IXa monoclonal antibody, inhibits flX conversion to
flXa, and has potent antithrombotic activity in a rat carotid artery thrombosis model
(Feuerstein, Nichols et al., 1997).
Active-site directed inhibitors of fXa include the natural anticoagulants, tick
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anticoagulant peptide (TAP) (Waxman, Smith et al., 1990)(Vlasuk, 1993), antistasin
(Dunwiddie, Thornberry et al.,1989)(Tuszynski, Gasic et al., 1987), Ancylostoma
caninum anticoagulant peptide (AcAP) (Cappello, Vlasuk et al., 1995), and synthetic
inhibitors such as DX 9065a (Hara, Yokoyama et al., 1995)(Hara, Yokoyama et al.,
1994) and YM 60828 (Taniuchi, Sakai, et al., 1998), exert their inhibitory effect by
binding competitively and reversibly to fXa. In addition to inhibiting free fXa, direct
inhibitors inactivate fXa bound to phospholipid surfaces (Krishnaswamy and Betz,
1997).
Heparin also inhibits intrinsic tenase (Barrow et al., 1994a); in plasma-free
systems, both unfractionated heparin and low molecular weight heparins inhibit the
activation of fX by a noncompetitive mechanism, but have no effect on
prothrombinase at therapeutic concentrations. In plasma systems, this antithrombin-
independent effect is largely overshadowed by the ability of heparin to catalyse the
inhibition by antithrombin of thrombin and fXa (Hirsh, 1991), and to a much lesser
extent, to catalyse the inhibition of thrombin by heparin cofactor II (Tollefsen, 1995).
To circumvent this problem we first chemically modified LMWH to reduce its
affinity for antithrombin, and demonstrated that the modified LMWH retains its ability
to inhibit intrinsic tenase. The aim ofthis project was to investigate the mechanism by
which LMWH inhibits these coagulation complexes so as to exploit these properties
in the development of a new inhibitor.
From the results given in Chapter 3, it was shown that hypersulphation of LA-
LMWH produces significant increases in the potency of the heparin. Hypersulphated
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LMWH was subsequently used to investigate the mechanism of inhibition of
prothrombinase and intrinsic tenase. The results revealed that the inhibition of intrinsic






4.1. Charge-dependent Mechanism of Inhibition :
Periodate oxidation, a technique which selectively cleaves bonds of non-sulphated
uronic acid residues (Young and Hirsh, 1990), and borohydride reduction were used to
modify LMWH so as to lower its antithrombin affinity by 1500-fold. Despite
eliminating the antithrombin-dependent properties of the LMWH, preliminary studies
in buffer systems demonstrated residual anticoagulant activity caused by the direct
inhibition of intrinsic tenase. Using this LA-LMWH, LMWH was N-desulphated using
a solvolytic desulphation technique (Inoue and Nagasawa, 1976).
At fixed concentrations of fIXa, fVIIIa, fX and PCPS vesicles, LA-LMWH caused
50% inhibition of the initial velocity of fX activation at a concentration of 16.3pg/ml.
Enoxaparin, a LMWH with normal antithrombin affinity, inhibited intrinsic tenase to
the same extent, with an IC50 of 13.2pg/ml. In contrast, N-desulphated LMWH had less
inhibitory potency, and a mean IC50 of 166pg/ml was obtained. These findings indicated
82
that the inhibition of intrinsic tenase was antithrombin-independent, but charge-
dependent, and raised the possibility that hypersulphation ofLMWHmight increase the
inhibitory potency. To test this hypothesis, LA-LMWH was hypersulphated using
sulphur trioxide as a sulphate donor. A series of LMWHs of increasing degrees of
sulphation, and increasing degrees of negative charge, were examined in assays of
intrinsic tenase activity. The results indicated that progressive hypersulphation of
LMWH increases the inhibitory potency of the glycosaminoglycan, reflected by
progressive reduction in the IC50 values. The most highly sulphated LMWH, "S5" was
found to be a 32-fold more potent inhibitor of intrinsic tenase than LMWH, with an IC50
value of 0.47|ig/ml. In addition, increasing the negative charge of the
glycosaminoglycan introduced prothrombinase inhibitory activity. The inhibitory
effects of our series of hypersulphated LMWHs were also examined in assays of
prothrombinase in buffer systems. A similar charge-dependent inhibitory effect was
found, with progressive hypersulphation ofLMWH increasing the degree of inhibition,
reflected by reduction in the IC50 values. The IC50 values of hypersulphated LMWHs
for prothrombinase were 2 orders of magnitude higher than those for intrinsic tenase
(IC50 values for "S5" of 0.47pg/ml (intrinsic tenase) and 30pg/ml (prothrombinase)),
demonstrating that the most potent inhibitory effect occurs towards the generation of
fXa by intrinsic tenase.
In plasma-based coagulation assays, hypersulphated LMWH demonstrated a
similar AT-independent inhibitory effect towards both intrinsic tenase and
prothrombinase. The APTT was used to reflect activity of intrinsic tenase and
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prothrombinase, and the fXa-clotting time was used as a measure of prothrombinase
activity. Both APTT and fXa-clotting times were prolonged in antithrombin-depleted
and control plasma to the same extent. In contrast, unfractionated heparin caused no
prolongation of either clotting time in plasma immunodepleted of antithrombin. The
plasma-based assays demonstrate that the inhibitory effects ofhypersulphated LMWHs
towards both intrinsic tenase and prothrombinase seen in buffer systems also occur
within plasma systems.
4.1.1. Effect of Sulphated Glycosaminoglycans on Blood Coagulation :
Less sulphated polysaccharides such as chondroitin sulphate, dermatan sulphate,
keratan sulphate and hyaluronic acid were observed to have no inhibitory effect on
intrinsic tenase (Barrow et al., 1994a). More highly sulphated polysaccharides, such
as dextran sulphate, possess an anticoagulant effect (Ricketts C.R., 1952); between
1-1.3 sulphate groups per glucose unit are required to cause maximum anticoagulant
activity. Similarly, sulphation of the natural polysaccharide, 'curdlan', creates active
P-l ,3-glucan sulphates, which produce a concentration dependent effect in APTT and
thrombin time assays (Alban et al., 1995). Additionally, Tiozzo et al. have
demonstrated in an APTT assay that N-desulphated heparins have a reduced
anticoagulant effect (Tiozzo et al., 1993). It was also demonstrated that as the degree
ofO-desulphation increases, both anticoagulant and antiproliferative effects (in baby
hamster kidney and smooth muscle cell lines) decrease. Likewise, unfractionated
heparin, LMWH, pentosanpolysulphate (a semi-synthetic sulphated polysaccharide),
and lactobionic acid (a synthetic polysaccharide) suppress the activity ofnatural killer
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cells, decrease lymphocyte cell size, alter cell surface structure at clinically relevant
dosages, and may interfere with the tumour killing process (Johann et ah, 1995). Thus,
hypersulphated LMWHs may have additional clinical benefits, for example in the
treatment ofthrombosis in patients undergoing management of malignant conditions.
4.2. Cofactor-dependent, Phospholipid-independent Mechanism of Inhibition
Prothrombinase and intrinsic tenase are multicomponent enzyme complexes;
taking into account the catalytic advantage conferred when all the components of the
enzyme complex are present (Mann, 1987; Mann et ah, 1988), it was possible to
determine rates of activation under conditions where individual components were
systematically substituted or removed. The effect of the most potent hypersulphated
LMWH, ' S5', as examined on the partially reconstituted activation complexes, to
investigate the components necessary for glycosaminoglycan sensitivity.
For both prothrombinase and intrinsic tenase, similar patterns of inhibition were
evident. In systems devoid of phospholipid, similar inhibitory effects were found to
those obtained with the complete enzyme complex, reflected by comparable IC50
values between the two systems. These findings indicated that the inhibitory effects
were not dependent on the presence of phospholipid.
To investigate these findings further, assays were carried out to determine the
effect of hypersulphated LMWH on prothrombinase activity and intrinsic tenase
activity using platelets in place of synthetic phospholipid vesicles.
Despite differences in the interaction of the comonents of prothrombinase and
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intrinsic tenase and their assembly on platelets and phospholipids (Kalafatis et al.,
1994; Gilbert and Baleja, J., 1995; London and Walsh, 1996), inhibition of the activity
ofthese enzyme complexes by hypersulphated LMWH was still observed, irrespective
of the membrane surface used.
4.3. Proposed Model for the Mechanism of Inhibition of Prothrombinase and
Intrinsic Tenase by Hypersulphated LMWH :
The inhibition of both prothrombinase and intrinsic tenase by hypersulphated
LMWH follows a "non-competitive" pattern of inhibition. A non-competitive inhibitor
can bind to a site on the enzyme other than the active site, and may cause a
conformational or deforming change in the enzyme such that the enzyme-substrate
complex can no longer be formed at its normal rate. (Lehninger, 1975; Wood et al.,
1981) Increasing the substrate concentration does not reverse the effect. The Michaelis
constant, Km is unaltered, and the Vmax is reduced. This is in contrast to competitive
inhibition, where the inhibitor binds at the same site (active site) of the substrate and
competes with it. Under such circumstances, the Km would be increased (increasing
the substrate concentration would reverse the inhibitory effect) and the Vmax would
remain unaltered, as the inhibitor does not interfere with the rate of breakdown of the
enzyme-substrate complex (Creighton, T.E., 1992). In this respect, hypersulphated
LMWH inhibits intrinsic tenase in the same manner as unfractionated heparin, which
also demonstrates a noncompetitive mechanism of inhibition in a purified buffer
system (Barrow et al., 1994a).
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In addition, kcat was found to be reduced for both enzyme complexes in the
presence of hypersulphated LMWH; the kcat value reflects the rate of product
formation by the enzyme-substrate complex and is proportional to the difference in
free energy between the ground state (Michaelis complex) and the transition state
(Chang et al., 1998). kcat, referred to as the 'turnover number', reflects moles of
substrate consumed per unit of time per mole of enzyme. For a multicomponent
enzyme, such as intrinsic tenase or prothrombinase, the functional enzyme
concentration is determined by the affinities and concentrations of the individual
components. Where all other components are saturating, the limiting component
reflects the enzyme concentration. Therefore, kcat represents the number of times each
enzyme molecule catalyses the reaction.
Determination of turnover numbers for prothrombinase and intrinsic tenase in the
presence of increasing concentrations of hypersulphated LMWH indicated a dose-
dependent inhibitory effect for both systems. In addition, there appears to be a
differential inhibitory effect, with almost complete inhibition of fXa generation by
intrinsic tenase, at concentrations of up to lOpg/ml. At concentrations of sLMWH
above a therapeutic range ( concentrations of >1000pg/ml), there is considerably
reduced, yet ongoing thrombin generation by prothrombinase.
To further determine the mechanism of inhibition, Km and kcatof the fXa/fVa
complex for prothrombin, and of the flXa/fVIIIa complex for fX were determined
kinetically in the absence and presence of sLMWH, at a concentration above the
determined IC50 value. For prothrombinase, in the presence of500pg/ml sLMWH, Km
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was unchanged (0.1 5pM), and kcat was reduced 3-fold. This pattern is consistent with
noncompetitive inhibition. A similar pattern of inhibition was seen with intrinsic
tenase; in the presence of 0.5pg/ml, kcat was reduced 8-fold, and the Km increased
minimally from 28 to 60nM.
The Kdapp, a measure of the affinity of enzyme or cofactor towards the
"substrate", in this case the affinity of the enzyme or the cofactor towards the rest of
the assembled enzyme complex, was found to be increased for prothrombinase by one
order of magnitude in the presence of hypersulphated LMWH, but was relatively
unchanged for an analogous system with intrinsic tenase.
Brandstetter's model of intrinsic tenase (Brandstetter et al., 1995), proposes that
the arched flXa molecule lies across the cofactor, fVIIIa, allowing the binding of fX
to the opposite side of fVIIIa, forcing fXa cleavage sites close to the substrate binding
site of flXa. Using this model to reflect intrinsic tenase and the analogous complex,
prothrombinase, there are two possible mechanisms of enzyme complex disruption,
which are schematically shown in figure 23.
a) Scheme 'A' (steric mechanism) involves disruption of the enzyme/cofactor
interaction by hypersulphated LMWH, in turn causing changes in the amount of flXa
complexed to fVIIIa at a given concentration ofproteins, reducing the effective enzyme
concentration. This mechanism, consistent with a cofactor-dependent, phospholipid-
independent, noncompetitivemechanism of inhibition would account for the reduction
in k<.at and Vmax seen with both assays of intrinsic tenase and prothrombinase in the
8S
SCHEME A
sLMWH causes disruption of the enzyme-cofactor interaction, at one or
several binding sites. This may reduce the effective enzyme concentration,
or may cause impaired binding between the substrate and the enzyme active
site.
Factor IXa
sLMWH binds to an exosite(s) on the enzyme causing impaired binding of
the substrate. Binding to the exosite may also weaken the affinity of the




Figure 23 : Proposed Models for the Mechanism of Inhibition of Intrinsic Tenase
by Hypersulphated LMWH.
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presence ofhypersulphated LMWH, and also accounts for the increase in Kdapp ofboth
enzyme and cofactor towards prothrombinase. The model does not, however, explain
the lack of change in Kd with intrinsic tenase.
b) Scheme 'B' (allosteric mechanism) involves hypersulphated LMWH binding to an
extended macromolecular binding site (exosite(s)) on the enzyme, causing impaired
binding of substrate, and possibly also cofactor, with subsequent reduction in the rate
of fX activation. This model is in agreement with the model of macromolecular
substrate recognition proposed by Krishnaswamy and colleagues in 1997
(Krishnaswamy and Betz, 1997; Betz and Krishnaswamy, 1998).
In support of Scheme 'B', studies using fluorescent derivatives of flXa have
shown a direct effect of fVIIIa on the catalytic activity of the enzyme (Mutucumarana
et al., 1992). The active site of flXa is positioned more than 70A above the
phospholipid surface; binding of fVIIIa does not alter the distance of flXa from the
surface, but does alter both the emission intensity and anisotropy of fluorophore-
labeled active site, suggesting that cofactor stimulation of flXa catalytic activity
results, at least in part, by conformational change in the active site when fVIIIa binds
to the enzyme on the phospholipid surface (Mutucumarana et al., 1992). This provides
evidence that disruption of enzyme and cofactor at sites away from the active site
could change the nature of the active site, and alter the catalytic rate of the enzyme
complex.
Factor VIII binding sites for flXa have been localised to amino acid residues
Ser558-Gln565 and Arg698-Ser710 of the A2 domain (O'Brien et al, 1995)(Fay et al, 1994)
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and residues 1811-1818 of the A3 domain (Lenting et al., 1996). Synthetic peptides
corresponding to each region inhibit intrinsic tenase activity of flXa, suggesting that
both sites are required for maximal affinity of fVIIIa for flXa (Lenting et al., 1996).
Factor IXa contains at least two interaction sites for fVIIIa (Lenting et al., 1994;
O'Brien et al., 1995) and equilibrium binding studies performed by Lenting and
colleagues have demonstrated a high affinity surface proximal interaction involving
the light chain of flXa and the light chain (A3-C,-C2 subunit) of fVIIIa, and a weak
affinity surface distal site involving participation of the catalytic domain of flXa and
the heavy chain subunit (A2 plus possibly A! subunit) of fVIIIa. Molecules of
sufficient negative electrical charge may disrupt such interactive sites by a charge-
dependent mechanism, altering the affinity of fVIIIa/IXa, and in turn, the effective
enzyme concentration.
Furthermore, knowledge of the effects of individual mutations within the different
regions of the fIX gene have provided insight into the function ofthe different domains
of flX (Giannelli et al., 1994). In particular, the importance of the first and second EGF
domains is demonstrated by the detrimental effects ofmany mutations found in these
domains (Kurachi et al., 1993). Recombinant DNA techniques have led to the
production of several chimeric molecules (Lin et al., 1990; Cheung et al., 1991;
Toomey et al., 1992; Zhong et al., 1994; Chang et al., 1995). Chang and colleagues
made a chimeric factor IX molecule containing the EGF-1 domain from fVII, fIXVIi
EGF1, which possesses increased functional activity in a one-stage clotting assay when
compared to recombinant wild-type flX (Chang et al., 1997). In vitro studies
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demonstrated that the increased activity is due to a higher affinity of flXViiEGFi f°r
fVIIIa, with a Kdapp one order of magnitude higher than recombinant wild-type fIXa,
and when infused into a dog with haemophilia B, the chimeric fIX exhibited a greater
than three-fold increase in clotting activity. Thus, disruption in critical binding sites
between enzyme and cofactor by a charge-dependent effect, or alternatively, changes
in conformation of the enzyme subsequently causing disruption of its interaction with
the cofactor, could lead to impaired binding of substrate, reducing the catalytic
efficiency of the enzyme complex.
Further evidence in favour of Scheme 'B' comes from studies using
recombinant techniques and cell culture. A mutant fIX molecule with arginine at
position 338 changed to alanine, possesses approximately three times greater clotting
activity than wild-type fIX. The major effects of the mutation were manifest only in the
presence of fVIIIa, causing a three-fold increase in kcat and a two-fold decrease in Km.
The mutant flX molecule had reduced affinity for heparin leading to the proposal that
Arg338 is part of an exosite that binds both fX and heparin (Chang et al., 1998).
Analogous to the well-characterised exosites on thrombin, which have multiple
functions including cofactor, substrate and heparin binding (Stubbs and Bode, 1993),
the a-helix 330-338 of flX is close to part of the region designated exosite II in
thrombin (Bode et al., 1992) which is involved in heparin binding. Using fluorescent
labelling techniques, the formation of a mucopolysaccharide/flXa complex was
characterised by a stoichiometry of 1:1 with a dissociation constant K„ IXa = 2.58 x 10"7
M. (Jordan et al., 1980). Thus, hypersulphated LMWH may bind to an exosite(s),
92
causing an unfavourable interaction during the initial binding of the substrate at the
active site, resulting in reduced kcat. Ifheparin binds to extended interaction sites on the
enzyme, disrupting enzyme-cofactor interaction, this model would take into account
the increase in Kdapp seen with kinetic assays of prothrombinase. However , this does
not explain the lack of increase in Kdapp seen with kinetic assays of intrinsic tenase.
At present, neither model 'A' nor 'B' fully explains all the observations noted in
this study, and further investigations are planned to further define the mechanism of
inhibition.
4.4. Future Directions :
Two models have been proposed to account for the cofactor-dependent, phospholipid-
independent, noncompetitive mechanism ofinhibition ofthe multicomponent enzymes,
prothrombinase and intrinsic tenase, yet neither model entirely accounts for all the
study observations. Future experiments will be performed to distinguish between these
two models to more thoroughly understand the mechanism of inhibition of sLMWH
on coagulation.
4.4.1. in vitro Studies:
Determination of the Effect ofsLMWH on the Enzyme-Cofactor Interaction, in the
Presence of Phospholipid : The inhibitory effect of hypersulphated LMWH on
prothrombinase and intrinsic tenase activity may involve a reduction in the affinity of
the enzyme-cofactor interaction. In addition to performing replicates of the assays to
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determine Kdapp of fVa and fXa towards prothrombinase, and fIXa towards intrinsic
tenase to aid statistical analysis ofsignificance, the following experiments are planned:
a. Factor VIHa-IXa Binding :
The binding of fVIIIa to flXa on phospholipid membranes can be monitored using a
fluorescent active site-blocked derivative of flXa, fluorescein-thioacetyl-maleimide-
FPR-IXa (Fl-M-FPR-IXa), which undergoes an increase in fluorescence anisotropy
when it binds fVIIIa (Barrow et ah, 1994)(Duffy et ah, 1992)(Mutucumarana et ah,
1992). Barrow and coworkers demonstrated that the binding of fVIIIa to flXa on
phospholipid membranes was not altered in the presence ofa heparin preparation which
consisted of a mixture with high and low affinity for antithrombin. From these
observations, Barrow and colleagues concluded that heparin does not inhibit intrinsic
tenase function by interfering with the formation of the fVIIIa/IXa complex. (Barrow
et ah, 1994a).
A similar experiment could be performed involving titration of fVIIIa (0-1 OOnM)
into a solution of PCPS (24-50pM) and 20nM f-FPR-IXa, in the absence or presence
of sLMWH, and monitoring the fluorescein fluorescence. In the absence of
phospholipid surface, fluorescence can not be used to monitor flXa interaction with
fVIIIa alone, since no change in intensity or anisotropy is observed (Duffy et ah, 1992).
These experiments could also be repeated in the presence of factor X.
b. Factor Va-fXa Binding:
There are several published spectroscopic methods which allow the determination of
the Kd values for fVa and fXa interactions with prothrombinase. The interactions of
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prothrombin, fXa and fVa with phospholipid vesicles can be quantified by light
scattering spectroscopy (Bloom et al., 1979). PCPS vesicles (20-50pM) are titrated
with increasing concentrations of ligand in the absence or presence of sLMWH, and
determination of light scattering intensity at 320nm after each addition. From plots of
relative molecular weight vs protein/phospholipid ratio, the Kd value can be
determined. The effect of sLMWH on fXa binding can also be studied by analysis of
the fluorescence intensity of the fluorescent fXa derivative, dEGR-fXa (dansyl-Glu-
Gly-Arg-fXa); the Kd for the interaction of fVa with dEGR.fXa on PCPS vesicles can
be determined by titration of fYa (O-lOOnM) into a solution of lOnM dEGR-Xa and
50pM PCPS whilst monitoring dansyl fluorescence (Krishnaswamy, 1990).
c. The Binding of sLMWH to Cofactors fV and fVIII, and Enzymes flXa and fXa:
Binding of hypersulphated LMWH to a site(s) on the enzyme would lend
support to model "B". Factor IXa binds to heparin-Sepharose columns at pH 7.4 more
tightly than fX or fVIII (Bloom, 1979) and it has been proposed that the binding of
heparin to intrinsic tenase occurs primarily via a binding site on flXa (Brandstetter et
ah, 1995). It would be important to determine the presence of binding sites on fXa, in
addition to factors Va and Villa by the same approach of affinity chromatography.
In addition, using the method of Jordan et al. (Jordan et ah, 1980), a fluorescent
label will be incorporated into a hypersulphated LMWH, that does not alter the
functional properties of the glycosaminoglycan. The labelled sLMWHwill be utilised
in conjunction with fluorescence polarisation spectroscopy to monitor its binding to
flXa, fXa and other coagulation proteins, and provide direct estimates of the
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stoichiometries and dissociation constants of these processes. Comparisons will be
made to N-desulphated LMWH, unfractionated heparin and LMWH (Jordan et al.,
1980).
d. Use of Coagulation Protein Variants:
Variant coagulation proteins, such as EGF and Gla-domainless fX (Rezaie and Esmon,
1994)(Morita and Jackson, 1986)(Sabharwal et al, 1997), chimeric flX (Chang et al.,
1997)) and fX proteins (Duffy et al.,1992b)(Cooper et al., 1997) and prethrombin-2
derivatives (Krishnaswamy and Walker, 1997), could be used in functional assays of
prothrombinase and intrinsic tenase, in the presence of sLMWH, to determine if
specific domains of each substrate, enzyme and cofactor may be implicated in the
inhibitory mechanism.
2. Determination ofthe Effect ofsLMWH on Cellular Surfaces :
The Effect of sLMWH on Prothrombinase and Intrinsic Tenase Using Activated
Monocytes as a Membrane Surface:
Mononuclear phagocytes constitute one of the major components in the cellular
infiltrates that characterise atherosclerotic, neoplastic and chronic inflammatory lesions
(Steinberg et al., 1991a)(Steinberg,1991b). Studying the response of monocyte
procoagulants to sLMWH is of importance for the characterisation of the inhibitory
effect in a biologically relevantmicroenvironment, and also to investigate the potential
role of sLMWH in the management of hypercoagulable states associated with
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atherosclerosis, inflammation and cancer (McGee et al., 1995).
Mononuclear cells will be isolated from the blood of human volunteers by
centrifugation through discontinuous (Percoll) density gradients (Boyum,
1968)(English and Andersen, 1974). Monocytes will be further separated from the
mononuclear cell population by centrifugation through hypertonic Percoll gradients
(45% Percoll in NaCl at 9.3mg/ml) as described previously (Boyum, 1968)(McGee et
al., 1995)(McGee and Li, 1991). Contaminating platelets will be removed using
differential centrifugation, and the cell populations isolated for use in kinetic
experiments will be determined by morphologic criteria using Wright's stain, and also
by flow cytometry. Assays of intrinsic tenase and prothrombinase will be performed
using continuous techniques as described in "Experimental Methods" (Section 2.2.2).
Experiments carried out to assess the effects ofdifferent chondroitin sulphates (CS) and
heparan sulphate on intrinsic tenase activity using activated monocytes as a surface
demonstrated that CS with 4,6-di-O-sulphated N-acetylgalactosamine
glycosaminoglycan structures inhibited intrinsic tenase activity (McGee et al., 1995).
It is anticipated that sLMWH will also inhibit intrinsic tenase and prothrombinase on
the monocyte surface.
4.4.2. In Vivo Studies : Animal Models
Hypersulphated LMWH has potential advantages over heparin and LMWH by its
potent ability to inhibit phospholipid-bound fXa and flXa. A ratmodel ofacute arterial
thrombosis has been designed (Klement et al., 1992) in which the distal aorta
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undergoes balloon injury. Tourniquets are used to isolate the damaged segment, and
thrombus produced by injecting 200pl recalcified rat blood with l25I-labelled rabbit
fibrinogen. Two aliquots ofblood will be recalcified in tubes, and following incubation
for 30 minutes at 37 °C, the mean of the weight and radioactivity will be used as a base¬
line of the initial weight and radioactivity of clots in the aorta. After allowing clot in
the aorta to age for 30 minutes, the tourniquet is removed, and external constriction is
applied around the aorta to reduce the blood flow. Animals will be randomly assigned
to receive a bolus and a 60 minute infusion ofsLMWH versus LMWH versus heparin,
in concentrations producing equivalent anti-fXa activity. Blood will then be collected
to measure the APTT and anti-Xa activity. After 60 minutes, animals will be sacrificed
and the clots in the aorta removed, weighed and counted. By subtracting values from
weight and radioactivity of the clots at the outset, the extent of clot accretion can be
determined. This model shows evidence ofconsiderable clot accretion in animals given
saline. It is anticipated that sLMWHwill be a potent antithrombotic in this model given
its unique mechanism of action.
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4.5. Summary and Perspectives
From the results of this study, I conclude that :-
1. In buffer systems, hypersulphated LMWH directly inhibits not only intrinsic tenase,
but also prothrombinase at concentrations used in therapeutic settings.
2. The mechanism of inhibition is charge-dependent; by causing an increase in the
negative charge, progressive hypersulphation ofLMWH increases the direct inhibitory
effect towards the activities of intrinsic tenase and prothrombinase.
3. Results from buffer systems have also been supported by plasma-based assays,
which show that hypersulphated LMWH has an antithrombin-independent inhibitory
effect on both enzyme complexes in plasma.
4. The mechanism of inhibition is cofactor-dependent and phospholipid-independent.
5. Data from kinetic studies demonstrate that hypersulphated LMWH inhibits intrinsic
tenase and prothrombinase in a noncompetitive manner.
From kinetic data, I have proposed two models, although data is at present
insufficient to support or refute eithermodel completely. I have also suggested further
studies to help elucidate the mechanism of inhibition further.
By directly inhibiting prothrombinase and intrinsic tenase activity, hypersulphated
LMWH can be added to a growing list of direct enzyme complex inhibitors, which
include active site-blocked fXa and fIXa (Benedict et ah, 1991; Wong et ah, 1997),
flXa antibodies (Feuerstein et ah, 1997) and active-site directed fXa
inhibitors(Tuszynski et ah, 1987; Vlasuk, 1993; Cappello et ah, 1995; Taniuchi et ah,
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1998). Hypersulphated LMWH may have potential clinical advantages over these
agents by inhibiting both fXa and thrombin generation simultaneously, with selectively
greater inhibition of fXa generation by intrinsic tenase.
Additionally, hypersulphated LMWHs may prove to be useful as scientific tools
in the laboratory; for these reasons, it is important that as much as possible is
understood about the mechanism of inhibition of this novel series of anticoagulants.
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Appendix (i)
Surface-mediated Enzymatic Reaction : "CLOTSPEED MODEL" to account for the surface-enhanced rate of
thrombin formation by the prothrombinase complex.
From the known binding parameters, the distribution of substrate and enzymatic components between bulk
solution and vesicle can be calculated for any concentration of substrate, enzyme and phospholipid.
In a physiological setting, most of the substrate (97%) is in solution; the remainder is associated with the vesicle
surface. The bound "substrate" contributes toward saturation of the vesicle surface. Formal local concentrations
of enzyme and substrate have been determined; using light scattering experiments, it has been shown that when
proteins bind to the phospholipid surface, the hydrodynamic radius of the phospholipid protein complex exceeds
that of the phospholipid vesicle, ie. a shell (interface shell) develops around a phospholipid vesicle, and within
this shell, formal local concentrations ofenzyme and substrate can be calculated in the region of the vesicle
surface. This model accounts for the remarkable rate enhancement seen with the assembly of the complex, the
phospholipid surface is "passive" and provides a locus for the condensation of enzyme, substrate and cofactor.
The co-concentration of substrate and enzyme increases the turnover number of substrate-enzyme complex by a






[Xa] = 0.1 jiM
[Va] = 0.7 (0.M
[II] = 1.8 mM
[Xa] = 0.06
[Va] = 0.5 m
O
Schematic diagram showing the distribution of substrate, fXa and fVa
between the bulk solution and the hypothetical "interface shell"
surrounding the vesicles. Local and bulk formal protein
concentrations are indicated. (Adapted from Nesheim, 1984)
(Nesheim, Tracy, et al. 1984), (Nesheim, 1984)
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Appendix (ii)
Inorganic Phosphate Assay (Ames. 1966")
Principle : The phosphomolybdate complex is reduced by ascorbic acid resulting in a colour change.
Reagents : (a) Ascorbic acid 10%
(b) 0.42% Ammonium molybdate.4 H:0 in 1M H2S04
"Mix" = 1 part of (a) to 6 parts of (b)
Procedure : 0.7 ml of the "mix" was added to 0.3 ml of phosphate solution in a small test tube and
incubated for 1 hour at 37°C ( or 20 minutes at 45°C). At 820nm, 0.01 pM inorganic phosphate
results in an absorbancy of 0.26, and the colour is stable for several hours. A standard curve can be
made as readings are proportional to phosphate concentrations.
All glassware must be scrupulously clean (free of phosphate), and tubes were acid-washed and rinsed
with distilled water before use.
Ashing Procedure for Total Phosphate
Principle : The sample of organic phosphate and a drop of magnesium nitrate solution are taken to
dryness in a small test tube by shaking the tube in a Bunsen burner flame. This procedure completely
ashes the organic phosphates, and the procedure can then be coupled with the sensitive inorganic
phosphate method described above.
Reagents : 10% Mg(NO3)2.6H20 in 95% alcohol
0.5M HC1
"mix" described in assay for inorganic phosphate
Procedure : 30pl of magnesium nitrate solution was added to 0.01 - 0.1 ml of phosphate sample
containing up to 70nmol of phosphate. The material was taken to dryness by shaking in a Bunsen
burner until the brown fumes disappeared. The tubes were then cooled to room temperature and
0.3ml of 0.5M HC1 added; the tube was capped with a marble and heated in a boiling water bath for
15 minutes to hydrolyse to phosphate any pyrophosphate formed in the ashing. After the tubes were
cooled, 0.7ml of "mix" was added, and the tubes were incubated as in the inorganic phosphate assay.
Absorbance was read at 820nm.
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Appendix (iii)
Determination of the Turnover Number for Intrinsic Tenase
(a) Determination of the Specific Activity of fXa towards the Chromogenic Substrate, N-methoxycarbonyl-D-norleucyl-L-
arginine-4-nitranilide-acetate (ChZX)
The assay was performed as follows:
I Opl of 0-1 OOOnM fXa was added to 90pl 400pM ChZX, and the change in OD monitored at 405nm for 5 minutes at RT. The
slope of the graph [Xa] vs change in OD/time = 7.87 mOD/min/nM Xa, and InM fXa = 0.00787 OD/min.
(b) Effect of Unfractionated Heparin on the Hydrolysis ofChZX byfXa
The assay was performed as follows:
80pl of 400pM ChZX was added to lOpl lOOnM fXa in the presence of a final concentration of l-1000pg/ml unfractionated
heparin. The change in optical density was monitored at 405nm for 5 minutes at RT.
No significant effect on the rate of hydrolysis was noted.
(c) Effect ofHypersulphated LMWH on the Turnover Numberfor Intrinsic Tenase
The catalytic rate of intrinsic tenase was determined by monitoring the rate of fXa generation using the chromogenic substrate,
Chromozym X. in a continuous assay, using the following final reactant conditions (Chang et al., 1997):-
fVIII/rVIIIa 0.48nM fX 192nM CaCI2 8mM PCPS41pM flXa, 2.5nM
ChZX 500pM
Albumin-free fVIII was activated by 2.5nM thrombin for exactly five minutes, and was added to a stock solution containing
calcium, fIXa and PCPS vesicles. 102pl of this stock solution was aliquoted into a flat-bottomed 96-well microtitre plate. A
series ofassays were performed simultaneously in the presence of increasing concentrations ofhypersulphated LMWH, and with
a control well using Tris-PEG 0.1% buffer in place of glycosaminoglycan.
Using a multichannel pipette, a final concentration ofChZX was added to the series of wells, and fX then added to initiate the
reaction. A final volume of200pl was used. The order of addition of reactants was critical.
Initial rates of chromogenic substrate hydrolysis were followed kinetically by monitoring the change in optical density every
II seconds on a Spectra-max 340 microplate reader, using the manufacturer's Softmax software. All reactions were monitored
at RT for five minutes, at 405nm.
Data Analysis
Data was analysed as in Section 2.2.10
Determination oftheMichaelis Constant (Km) for Intrinsic Tenase, at Saturating Concentration ofPhospholipid Vesicles,
in the Absence and Presence of Hypersulphated LMWH.
The Km, a measure of the affinity of the fVIIIa/flXa complex for the substrate, fX, was determined by measuring fXa generation
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in the reaction that contained :-
(Villa 0.48nM fLXa 2.5nM CaCI25mM PCPS41pM ChZX 500pM
fX 0-384nM
A series of nine dilutions of fX were made giving a concentration range of 1 -400nM.
0.48nM fVIII was activated with InM thrombin for exactly five minutes. 48jj.I of this solution was added to a stock containing
54pl CaCh, fiXa^and PCPS vesicles in a microtitre well plate, to which 50pl ChzX was added. 50pl of fX was added to initiate
the generation of fXa, in a final reaction volume of200pI.The procedure was simultaneously repeated in the presence of0.5 and
0.25pg/ml V20S. Assays were performed in duplicate.
Changes in optical density at 405nm were monitored for 5 minutes on a Spectra-max 340 micro-plate reader, at room
temperature, and converted to the fXa generation rate.
Data Analysis
See Section 2.2.11
Determination of the Apparent KdIX, for Intrinsic Tenase at Saturating Concentration of Phospholipid Vesicles, by
Increasing the Enzyme Concentration in the Absence and Presence of Hypersulphated Heparin.
The apparent Kd of fIXa for intrinsic tenase, at saturating concentrations of PCPS vesicles, (a measurement of the affinity of
fIXa towards the intrinsic tenase complex), was determined by measuring the rate of fXa generation in the reaction that contained
fVIIIa 0.48nM fXI92nM PCPS vesicles 41 pM CaCI25mM ChZX SOOpM
flXa, 0-50nM
The assay was performed as follows :
A series of ten dilutions of50pl fIXa were made in Eppendorf tubes, to which CaCl2 and PCPS vesicles were added. 48pl fVIll
was then activated using InM thrombin for exactly 5 minutes at room temperature. The fIXa/calcium/PCPS mixture was then
aliquoted into a series ofmicrotitre wells, to which the fVIII mixture was added. 50pl ChZX was then added to the ten wells
simultaneously using a multichannel pipette, and 50pl fX was subsequently added to initiate the reaction. The procedure was
simultaneously carried out in the presence of 0.25pg/ml V20S.Assays were performed in duplicate.
Changes in optical density at 405nm were monitored for 5 minutes on a Spectra-max 340 micro-plate reader, at room
temperature, and converted to the fXa generation rate.
Data Analysis See section 2.2.12
Appendix (iv)
Tyrode's modified buffer (TMB)(pH 7.5): (Yuan,Y et al.,1996)
104
Reagent























Procedure for counting cells in haemacytometer
50pl ofcell suspension was added to 50pl trypan blue and mixed. lOpl of this mixture
was placed on a haemacytometer counting slide and the cells counted as indicated.
Note: Any cells that stain blue in the presence of trypan blue have died.
B
If cells in one very large square A are counted:
# cells in A x dil factor x 104 = # cells /ml
If cells in one square (B) are counted :
# cells in B x 25 x dil factor x 104 = cells/
106
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